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The treatment of inflammatory bowel disease (IBD) has been
revolutionised over the past decade by the increasing
use of immunomodulators, mainly azathioprine (AZA)/6-
mercaptopurine (6-MP) and methotrexate (MTX), together
with the advent of biological therapy. Immunomodulators are
being usedmore often and earlier in the course of the disease.1
The introduction of biologic agents, especially inhibitors of
the key proinflammatory cytokine, tumor necrosis factor alpha
(TNF-α) initiated a new therapeutic era, whose use has grown
continuously since their introduction in 1998.2 With such
immunomodulation, the potential for opportunistic infection
is a key safety concern for patients with IBD.
Opportunistic infections pose particular problems for
the clinician: they are often difficult to recognise and are
associated with appreciable morbidity or mortality, because
they are potentially serious and hard to treat effectively.
Enhancing awareness and improving the knowledge of
gastroenterologists about opportunistic infections are impor-
tant elements to optimise patient outcomes through the
development of preventive or early diagnostic strategies.
A long list of opportunistic infections has been described
in patients with IBD. Many questions remain unanswered, not
only concerning the need for screening, preventive measures
or the best diagnostic approach, but also on appropriate
treatment and management of immunomodulator therapy
once infection occurs. This led the European Crohn's and
Colitis Organisation (ECCO) to establish a Consensus meeting
on opportunistic infections in IBD. The formal process of a
Consensus meeting has been described,3 but the purpose is
to quantify expert opinion in the context of a systematic
review of existing evidence. To organise the work, infectionswere classified into six major topics (see plan). Specific
questions were asked for each infectious agent. The
different topics were distributed to working groups that
comprised junior and senior gastroenterologists with infec-
tious disease experts. Each group performed a systematic
review of the literature and answered questions on their
topic, using recommendation grades and levels of evidence
according to the Oxford Centre for Evidence Based Medicine.
A two-day meeting in December 2007 with all participants
fashioned the ECCO Statements after tough discussion
(Anonymous, Centre for Evidence Based Medicine, Oxford.
Levels of evidence and grades of recommendation. http://
www.cebm.net/levels_of_evidence.asp.). This paper is
therefore the product of work by gastroenterologists and
infectious disease experts. It provides guidance on the
prevention, detection and management of opportunistic
infections in patients with IBD. After a section on definitions
and risk factors for developing opportunistic infection, there
are five sections on different infectious agents, followed by a
section on information and guidance for patients with IBD
travelling frequently or to less economically developed
countries. In the final section, a systematic work up and
vaccination programme is proposed for consideration in
patients exposed to immunomodulator therapies.
The proposals may appear relatively radical, with the
potential for major impact on current practice, but we
believe that these recommendations will help clinicians
optimise patient outcomes by reducing morbidity and
mortality related to opportunistic infections in patients
with IBD. Since local antibiotic resistance, availability and
practice varies, doses of specific drugs are not included.
Local guidelines or specialist advice on dose and adminis-
tration should be consulted as appropriate.
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2.1. Definition of an immunocompromised patient
An immunocompromised host has an alteration in phagocy-
tic, cellular, or humoral immunity that increases the risk of
an infectious complication or an opportunistic process.
Patients may also be immunocompromised if they have a
breach of their skin or mucosal defence barriers that permits
microorganisms to cause either local or systemic infection.4
There is no clearcut definition of an immunocom-
promised state. Three categories are recognised by the
Centers for Disease Control,5 depending on the severity of
immunosuppression:
1. Persons who are severely immunocompromised not as a
result of HIV infectionSevere immunosuppression can be
the result of congenital immunodeficiency, leukaemia,
lymphoma, generalised malignancy or therapy with
alkylating agents, antimetabolites, radiation, or large
doses of corticosteroids (2 mg/kg body weight, or
N20 mg/day of prednisolone, Section 2.4.1)
2. Persons with HIV infection
3. Persons with conditions that cause limited immune
deficits (conditions include hyposplenism and renal fail-
ure, among others.)
2.2. Definition of opportunistic infection
An opportunistic infection may be defined as a serious,
usually progressive infection by a micro-organism that has
limited (or no) pathogenic capacity under ordinary circum-
stances, but which has been able to cause serious disease as a
result of the predisposing effect of another disease or of its
treatment.6 They are sometimes known as infections of
unusual occurrence.
2.3. Whatmakes an IBDpatient immunocompromised?ECCO Statement OI 2A
IBD patients should not be considered systemically
immunocompromised in the absence of immunomo-
dulatory therapyormalnutrition [EL5, RGD], despite
evidence for a defect in mucosal innate immunity.
IBD patients on different immunomodulators are
probably not equally immunocompromised, but
there is currently no single method of evaluating
the degree of immunosuppression [EL5, RG D]There is increasing evidence of an aberrant innate im-
mune response occurring proximally and leading to T-cell
activation in IBD.7 Evidence includes decreased defensin
expression by Paneth cells, impairment of neutrophil
chemotaxis and decreased candidacidal or bactericidal
functions. Changes in intestinal barrier function, down-
regulation of junctional complexes and defect in NOD2
pathways contribute substantially to defective innate im-
munity.8,9 Description of the numerous mechanisms con-
tributing to this dysimmunity is beyond the scope of thisarticle. It is notable, however, that preliminary clinical
trials of treatments that may stimulate immunity have
yielded positive results, which further supports the concept
of defective innate immunity in IBD.10,11 Despite evidence
of defective mucosal immunity, there is no proof of a
systemic immune defect in patients with IBD in the
absence of concomitant immunomodulator therapy.
Patients with IBD are therefore rendered immunocom-
promised through their treatment. Immunomodulators com-
monly used in inflammatory bowel disease are
corticosteroids, azathioprine, methotrexate, calcineurin
inhibitors, anti-tumor necrosis factor agents, or other
biologics. Their modes of action differ, but they all
compromise to some extent the patient's immune response.
Unfortunately there is no biological means of measuring the
degree of immunosuppression in patients with IBD. According
to the Centers for Disease Control, IBD patients belong to
category '1' (Section 2.1).2.4. Risk factors for developing an
opportunistic infectionECCO Statement OI 2B
Those particularly at risk for opportunistic infections
are patientswith combinations of immunomodulator
therapies [EL3b, RG C] and those with malnutrition
[EL4, RG D], whichmay be linked to disease severity.
In addition, comorbidities should be considered. Age
may be an independent risk factor for opportunistic
infections in IBD [EL5, RG D]
Predisposing factors not only lower the patient's
resistance to opportunistic infection, but enable the
infection to develop and progress to an extent that is not
otherwise seen.6 In the IBD literature, very few data are
available regarding risk factors for developing an opportu-
nistic infection. Information was therefore collected from
such IBD literature as there is, as well as from patients with
rheumatological disease and from the general population.
We have defined two categories of risk: those that are
external to the patient (immunomodulator therapy, expo-
sure to pathogens, or geographic clustering) and those
that are inherent to the patient (age, comorbidity and
malnutrition).
2.4.1. Immunomodulator therapyECCO Statement OI 2C
The immunomodulators commonly used in IBD and
associated with an increased risk of infections
include corticosteroids, thiopurines,methotrexate,
calcineurin inhibitors, anti-TNF agents and other
biologics [EL1, RG A]. For corticosteroids, a total
daily dose equivalent to≥20mg of prednisolone for
≥2 weeks is associated with an increased risk of
infections [EL2, RG B]
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been associated with the use of immunomodulator therapy
in IBD. Despite different mechanisms of action, any of those
drugs can lead to any type of infection. No strict correlation
between a specific immunomodulator drug and a certain
type of infection has been observed. For example, an
increased risk of granulomatous infections is generally
attributed to anti-TNF therapy, but in a meta-analysis of
serious infections during anti-TNF therapy, only 12 of the
126 reported infections were identified as granulomatous.12
Toruner and colleagues found that corticosteroid use was
more commonly associated with fungal (Candida spp.)
infections, azathioprine with viral infections and anti-TNF
therapy with fungal or mycobacterial infections.13 There
was, however, considerable overlap. Furthermore, these
drugs are commonly prescribed together, so the infectious
event might be the consequence of cumulative immuno-
suppressive activity.
Data that identify immunomodulators as risk factors for
opportunistic infection come mainly from the rheumatologic
literature.14 For corticosteroids there are no precise data in
the IBD population that identify a dose associated with
increased risk of infection. Nevertheless, the risk of post-
operative infections has been clearly linked to concurrent
use of corticosteroids in IBD patients undergoing elective
surgery.15 In rheumatologic patients, a dose-related,
increased risk of infection is associated with concurrent
corticosteroids.16,17 The overall risk of infection increases
for doses of prednisolone N10 mg/day, or cumulative dose
N700 mg. In addition, a duration of steroid therapy N2 weeks
predisposes to infections.18
Each immunomodulator carries an increased risk of
infection, although to a varying degree that has not yet
been quantified. Of fundamental importance is the
observation that combinations of immunomodulator ther-
apy are associated with an incremental increase in the
relative risk of opportunistic infection (three fold in-
creased risk (OR 2.9, 95% CI 1.5–5.3) of opportunistic
infection if any one immunomodulator was used, increasing
substantially (OR 14.5, 95% CI 4.9–43) if two or more drugs
were used concomitantly).13
2.4.2. Exposure to pathogens and geographic clusteringECCO Statement OI 2D
Exposure to pathogen is a risk factor for opportu-
nistic infection in the immunocompromised popu-
lation. Avoiding close contact with pathogens and
endemic areas may be beneficial in reducing the
risk of infection in IBD patients [EL5, RG D]. Special
consideration should be given to patients from
endemic areas, or patients who do not respond to
immunomodulators as expected
For pathogens that are ubiquitous, it is impractical to
reduce exposure. However, it is logical to avoid high intensity
exposure (such as sharing a room with a person, including
a child, with active infection). Living in an area where
tuberculosis or other diseases such as histoplasmosis orcoccidioidomycosis are endemic, inevitably increases the
risk for contracting an opportunistic infection in the normal
population, let alone those who are on immunomodulator
therapy.19 Consequently special attention should be given to
patients travelling to or living in areas of endemic infection.
This is specifically addressed in Section 8. Several micro-
organisms have been shown to be capable of replicating in
water. In addition, both municipal water and ice cubes in
drinks have been the source of nosocomial outbreaks of
infection. In less economically developed countries, the im-
munocompromised patient may best be advised to avoid tap
water and ice made from tap water.20
2.4.3. Age
Immunosenescence is defined as the state of dysregu-
lated immune function that contributes to an increased
susceptibility of the elderly to infection and possibly to
autoimmune disease and cancer.21 In this population, there
is good evidence of functional alterations in cells from the
innate and adaptative immune systems.22–25 Despite this
background, there is surprisingly little evidence that
immune dysregulation has direct relevance to the infec-
tions commonly seen in the elderly population, except for
reactivation of tuberculosis and decreased effectiveness of
influenza vaccination in the elderly.
On the other hand, there are data to demonstrate that
certain infections are more prevalent in the elderly than in
younger adults. This increased prevalence ranges from 3–20
fold for community-acquired pneumonia and urinary tract
infections respectively. The most commonly encountered
infections in the elderly are from pyogenic bacteria. In
contrast (and perhaps notable from an immunopathogenic
perspective), viral infections are rare in comparison with the
younger population, with the specific and again notable
exceptions of influenza, reactivation of herpes zoster and
viral gastroenteritis.22
Although increasing age is without doubt a risk factor for
infection in the general population, it is surprising that this
was not found in many series,26,27 although, a single case–
control study of 100 patients identified age N50 as a further
predisposing factor (OR 3.0, 95% CI 1.2–7.2 relative to age
b25 years). This is an important practical consideration.13 It
is of greatest importance to remain cautious when treating
this subgroup of the IBD population, especially with anti-TNF
therapy. Increasing age has also been identified as a
significant predictor of infection in a cohort with rheuma-
toid arthritis.16
2.4.4. Comorbidities
Four comorbidities have been identified as significant risk
factors for infection in rheumatoid arthritis patients: chronic
lung disease, alcoholism, organic brain disease and diabetes
mellitus.16 No relevant comorbidities have been associated
with infections in patients with IBD. It seems likely that this
reflects the youthful age and limited co-morbidity of most
patients with IBD, and as with age, pragmatic caution is again
advisable when considering immunomodulator therapy in
patients with comorbid conditions.
2.4.5. Malnutrition
Malnutrition appears to be the major cause of decreased
immune function worldwide. It is not only a major risk factor
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important cause of malnutrition, because it increases
metabolic demand over a long period.22 Without adequate
nutrition, the immune system is deprived of the components
needed to generate an effective immune response. The
immune response can in turn influence nutritional status,
since TNFα has a profound influence on nutrient absorption
and metabolism.28
Nutritional deficiency is associated with impaired cell-
mediated immunity, as well as decreased phagocyte func-
tion, cytokine production, secretory antibody affinity and
response, and impairment of the complement system.29
Immune disorders related to nutritional deficiency range
from increased opportunistic infections and cancers to
suboptimal responses to vaccinations.28 Consistent with
cause and effect, supplements of micronutrients improve
immune responses, reduce the incidence of respiratory
infections and ameliorate the impaired response to vaccina-
tion.30 Nutritional deficiency is common in Crohn's disease
and micronutrient deficiency (such as to zinc, copper, or
selenium) often go unrecognised.
A person at “nutritional risk” is someone whose
consumption and/or absorption of specific nutrients is
deficient.28 Numerous factors contribute to malnutrition in
IBD: anorexia (due to increased levels of cytokines); drug–
nutrient interaction (corticosteroids decrease intestinal
absorption and increase renal excretion of calcium;
sulphasalazine decreases folate absorption); malabsorp-
tion (bacterial overgrowth causing steatorrhoea affects
fat-soluble vitamins and B12 absorption); inadequate
intake (fear of abdominal pain, or altered taste sensation
with metronidazole); reduced caloric intake due to partial
small bowel obstruction; ileal resection (vitamin B12); and
jejunal disease or resection (iron deficiency), let alone
short bowel syndrome.31
Depressed cellular immunity has been observed in
malnourished CD, both in vivo and in vitro.32 Nevertheless,
the correlation between malnutrition and risk of infection
has not been extensively studied in IBD. Yamamoto found an
increased risk of intra-abdominal septic complications in
patients with an albumin level of b30 g/L.33 It is still unclear
whether this was cause or consequence, since a low serum
albumin often reflects decreased synthesis as a consequence
of infection or disease activity and is not a good way of
assessing malnutrition in IBD patients. By comparison, a low
serum total protein or albumin has been associated with
opportunistic infection in patients with polymyositis or
dermatomyositis.34
Better measures of nutritional status are the body mass
index (BMI) and the simple expedient of asking a dietitian
to conduct a formal nutritional assessment of intake and
expenditure. Evaluation is readily achieved when a
dietitian is part of the IBD service, conducting a clinic
parallel to an IBD clinic. Formal dietetic assessment when
starting immunomodulator therapy (or, indeed when con-
sidering surgery) in those with a BMI b20 kg/m2 is some-
thing that rarely occurs to a gastroenterologist. Since
nutritional support can reverse the impact of malnutrition
on impaired immune function, it is a practical measure that
should readily be implemented. The lack of evidence sup-
porting this approach simply reflects the lack of research in
this area.3. Hepatitis C virus, hepatitis B virus and human
immunodeficiency virus
3.1. Hepatitis C virus (HCV) infectionECCO Statement OI 3A
No Consensus could be reached for HCV screening
prior to starting immunomodulators. Immunomo-
dulators are not necessarily contraindicated in
active chronic HCV (HCVAb+, HCV RNA+). The
decision depends on the severity of IBD and the
stage of the liver disease
Acute HCV infection should be treated according
to standard practice without stopping immuno-
modulators [EL5, RG D]3.1.1. Background
The hepatitis C virus (HCV) is a hepatotropic RNA virus
that belongs to the family flaviviridae. In Europe it is esti-
mated that 0.2–2% of the population is infected with HCV. In
most cases transmission of hepatitis C virus occurs parent-
erally. Sexual, perinatal, and sporadic transmission are
reported, but infrequent. Acute HCV infection is often
asymptomatic without jaundice. Chronic HCV infection
develops in about 85% of all cases. Among patients with
chronic HCV infection, 20% develop liver cirrhosis within
20 years of disease duration, with a high rate of hepatocel-
lular carcinoma (1–2% per year).
3.1.2. Impact of immunomodulator therapy on the natural
history of the disease
The effect of corticosteroids on the course of HCV infec-
tion in IBD patients has not been studied. Data from liver
transplant patients suggest that slow tapering of steroids
after liver transplantation for patients with HCV infection
should be recommended, to improve HCV-related liver
disease.35 It is reasonable to assume, therefore, corticoster-
oids used in the treatment of IBD, have no detrimental effect
on the course of HCV.
The impact of azathioprine on HCV infection in IBD
patients has also not been evaluated. It has been demon-
strated in vitro that azathioprine has antiviral activity
against flaviviridae, including HCV.36 Once again, extrapo-
lating from patients undergoing liver transplantation for HCV
infection, azathioprine can be used in IBD patients infected
with HCV. As for methotrexate, a small series of hepatitis C
patients with arthropathy showed no detrimental effect
from treatment with methotrexate.37
Likewise, the role of TNF-α in the regulation and replication
of HCV is unclear. Case series suggest that anti-TNF therapy has
no adverse effect or might even improve HCV infection.38–42
Peterson presented data on 22 HCV patients treated with
either infliximab or etanercept for rheumatoid arthritis.43
There were no significant differences between liver function
tests and viremia assessments at baseline and follow up.
The best evidence that anti-TNF therapy might be bene-
ficial for HCV infection comes from a study of etanercept as
an adjuvant to interferon and ribavirin therapy for naïve
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to improve virological response to a combined IFN-α2b/
ribavirin therapy in these patients.
3.1.3. Preventive measures
General measures to reduce or prevent HCV infection are
appropriate, since vaccination or chemoprophylaxis for
potential infection is not available.
3.1.4. Diagnostic approach, screening and treatment of
underlying infection
Diagnostic approach and screening
No Consensus could be reached for HCV screening
(including HCV antibody testing or HCV PCR in the
event of positive antibody testing) prior to starting
immunomodulators.
Treatment of the infection
Immunodulators can be used in IBD patients regardless of
concomitant HCV infection. On the other hand, antiviral
treatment for HCV infection in conjunction with Crohn's
disease is generally not recommended, since interferon
therapy may worsen disease, although this remains con-
troversial.45 This is in contrast to ulcerative colitis where
interferon therapy does not appear to have an adverse
affect.46
3.1.5. Infection occurring during immunomodulator therapy
There are no reports of acute HCV infection developing
during immunomodulator therapy. Interruption of immuno-
modulator therapy is not necessarily recommended.
3.2. Hepatitis B virus (HBV) infectionECCO Statement OI 3B
HBV vaccination is recommended in all HBV
seronegative patients with inflammatory bowel
disease. Efficacy of hepatitis B vaccination is
influenced by the number of immunomodulators
given [EL3b, RG B]. Higher doses of the immunis-
ing antigen may be necessary to achieve success
[EL3b, RG C]. Serological response should be
measured after the completion of vaccination
ECCO Statement OI 3C
Before and during immunomodulator treatment,
HBsAg+ carriers should receive pre-emptive ther-
apy with anti-viral agents (nucleoside/nucleotide
analogues) regardless of the degree of viremia in
order to avoid hepatitis B flare [EL4, RG D]ECCO Statement OI 3D
All IBD patients should be tested for HBV (HBsAg,
anti-HBs, anti-HBcAb) to rule out HBV infection
[EL5, RG D]ECCO Statement OI 3E
Patients with evidence of chronic active HBV
infection should receive standard antiviral therapy
[EL1, RG B]. As IFN therapymight worsen underlying
inflammatory bowel disease, nucleoside/nucleotide
analogues should be used preferentially [EL5, RG D]ECCO Statement OI 3F
There is no established treatment for acute HBV
infection. Immunosuppressive therapy should be de-
layed until resolution of acute infection [EL5, RG D]3.2.1. Background
Hepatitis B (HBV) virus is a hepatotropic DNA virus
belonging to the Hepadna virus family. HBV is transmitted
parenterally, sexually, and perinatally. Approximately 70% of
patients with acute hepatitis B have anicteric or subclinical
hepatitis, while the remainder present with icteric hepatitis,
or occasionally fulminant hepatic failure. The rate of pro-
gression from acute to chronic hepatitis B depends largely on
the age of infection. It is estimated at 90% for infection
acquired perinatally and 20–50%, or 5% for infection at age
1–5 years or during adulthood, respectively.47–50 Chronic hepa-
titis B is characterisedby viral replication inhepatocytes and the
immune response towards the virus, with consequent hepatitic
necrosis and inflammatory response. The early phase of chronic
HBV infection features high viral replication associated with
active liver disease, while the later, low replicative phase is
characterised by remission of overt liver disease. In contrast,
patients with perinatal HBV infection exhibit another clinical
course during their early decades, with active viral replication
and the absence of hepatic injury, which is considered an
immunotolerant phase of disease. It is important to note that
even in patients who recover from acute hepatitis B, HBV DNA is
still detectable in the hepatocytes of most patients.51 In some
of these patients traces of HBVDNA are detectable in peripheral
blood many years after resolution of acute hepatitis B.52,53
A flare of HBV infection refers to an abrupt increase
transaminases in patients with chronic hepatitis B. Acute
flares reflect an increase in the immune response against
HBV, which might explain why flares of disease are pre-
dominantly associated with withdrawal of immunosuppres-
sive therapy (e.g. corticosteroids or cytotoxic agents). They
rarely occur during immunosuppression. Indeed, corti-
costeroid ‘priming’ (a deliberate short course of corticoster-
oid treatment followed by abrupt withdrawal) has been
evaluated as a strategy to increase the response rate towards
antiviral therapy in HBV, although ineffective. Post-steroid
flares have been associated with hepatic decompensation.
3.2.2. Impact of immunomodulator therapy on the natural
history of the disease
The effect of corticosteroid, immunomodulator, or anti-
TNFα therapy on the course of HBV infection in IBD patients has
not been studied prospectively. Consequently, recommenda-
tions for the management of chronic HBV infection during im-
munomodulator therapy are based on observations in patients
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tions, or cytotoxic treatment of solid tumors or haematologic
malignancies, as described by societies including the American
Association for the Study of Liver Disease (AASLD).54 Data
derived from HBsAg+ cancer patients indicates that reactiva-
tion of HBV replication occurs in 20–50% of hepatitis B carriers
undergoing immunosuppressive or cancer chemotherapy. Most
are asymptomatic flares, but icteric flares and even hepatic
decompensation or death have been observed.54 Reactivation
of HBV replication in patients treated for lymphoma are more
common when chemotherapy regimens include corticoster-
oids.55 There are case reports of symptomatic and severe HBV
flares in HBsAg+ IBD patients receiving infliximab.56–58 One
report has described HBV reactivation in an anti-HBcAb+ and
HBsAg− patient.59
3.2.3. Preventive measures
Seronegative patients
HBV vaccination is recommended in all seronegative IBD
patients, because of the potential consequence of steroids
or immunomodulator therapy should HBV be acquired. It is
reasonable to take the risk of acquiring HBV into account.
Seropositive patients with prior evidence of HBV infection
HBsAg+ patients: In chronic HBsAg+ carriers, prophylactic
antiviral treatment with nucleotide/nucleoside analogues
is recommended, best started 2 weeks prior to the intro-
duction of steroids, azathioprine, or anti-TNFα therapy and
continued for 6 months after their withdrawal. In line with
recommendations from AASLD, patients with high baseline
HBV DNA levels (N2000 IU/mL), should continue antiviral
treatment until endpoints applicable to immunocompetent
patients are reached, according to specific guidelines for
HBV treatment. Most data exists for lamivudine, but other
nucleotide/nucleoside analogues may be used. If immuno-
modulator therapy (such as azathioprine) is expected to
last N12 months, nucleotide/nucleoside analogues with a
lower propensity than lamivudine for provoking drug-
resistant mutations of HBV DNA might be preferred.
Interferon-alpha (IFNα) is best avoided for two reasons:
first, IFNα may exacerbate Crohn's disease and second,
IFNα may cause additional bone marrow suppression.
HBsAg− patients: HBV reactivation may occur in patients
who are HBsAg-negative but anti-HBc and anti-HBs-posi-
tive, as well as in those with isolated anti-HBc. Since this is
infrequent and information in the patient population
receiving cytotoxic or immunosuppressive therapy is
limited, routine prophylaxis for these individuals is not
recommended.60,61 Such patients should be monitored
routinely for elevation of AST/ALT, as well as for changes
in HBV serology and HBV DNA as clinically indicated.
3.2.4. Diagnostic approach, screening and treatment of
underlying infection
Diagnostic approach and screening
All IBD patients are best tested for HBV infection (HBsAg,
anti-Hbs Ab, anti-HBcAb) to assess infection or vaccination
status. In patients presentingwith evidenceofHBV infection,
HBeAg, anti-HBe, and HBV DNA should be assessed as re-
commended by local guidelines for the management of HBV.
Treatment of chronic HBV infection
Treatment with IFN-α of chronic active HBV infection and
concomitant Crohn's disease is generally not recommended,because IFN-α may exacerbate Crohn's disease. Patients
with ulcerative colitis and concomitant HBV infection may
receive IFN-α, since an adverse effect on the course of IBD is
less likely.46 Nucleotide/nucleoside analogues have not been
tested in IBD patients on immunomodulator treatment, but
case series suggest that they are safe and effective.
3.2.5. Infectionoccurring during immunomodulator therapy
There are no reports of newly acquired (acute) HBV in-
fections during immunomodulator or biological therapies.
Apart from fulminant hepatitis, where expert opinion has
advocated nucleotide/nucleoside treatment, there is no
established treatment for acute HBV infection. HBV infec-
tion in adults resolves in the vast majority of patients.
Corticosteroids may increase the replication rate of HBV by
direct effects on viral replication as well as inhibition of
the immune response andmightworsen disease or increase the
chance of chronic infection. The effect of immunomodulators
on acute HBV infection has not been studied prospectively.3.3. Human immunodeficiency virus (HIV) infectionECCO Statement OI 3G
Testing for HIV should be considered for patients
with inflammatory bowel disease prior to starting
immunomodulator therapy, based on anecdotal
reports of increased risk and severity of HIV-
related infections in patients receiving immuno-
modulator therapy [EL4, RG D]. Re-testing is
indicated for patients at high-riskECCO Statement OI 3H
The diagnosis of inflammatory bowel disease in HIV-
positive patients, should be reviewed and treat-
ment managed in conjunction with appropriate
specialists [EL5, RG D]. Treatment of HIV in patients
with inflammatory bowel disease, including che-
moprophylaxis, should follow standard guidelines
[EL1, RG B]. Immunomodulators are not necessarily
contraindicated in HIV-positive patients [EL4, RG D]3.3.1. Background
The human immunodeficiency virus (HIV) belongs to the
human retrovirus family. The hallmark of HIV is transcription
of its genomic RNA to DNA by an enzyme called ‘reverse
transcriptase’. Infection is mediated by binding of viral gp120
to the CD4 co-receptor that is expressed on the surface of CD4+
T helper cells, monocytes/macrophages and dendritic cells.
Certain co-receptors such as CCR5 and CXCR4 are mandatory
for viral entry. The consequence is a progressive quantitative
and qualitative deficiency of T-helper cells and a subsequent
impairment of T-cell mediated immune responses. If T-helper
cell concentrations ultimately decline below a certain thresh-
old, patients are at high risk of developing opportunistic
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defining illnesses. Transmission of HIV occurs by homo- or
heterosexual contact, blood or blood products and by infected
mothers to their infants, whether intrapartum, perinatally, or
via breast feeding. The clinical manifestations of HIV infection
comprise a broad spectrum from an acute HIV syndrome
associated with primary infection, to a prolonged phase of
clinical latency, to the state of symptomatic advanced disease.
Thanks to highly active anti-retroviral therapy (HAART), viral
replication can be effectively suppressed, so that an almost
normal immune status can be regained in HIV-infected
patients.
3.3.2. Impact of immunomodulator therapy on the natural
history of the disease
The effect of corticosteroids on the course of HIV infec-
tion in IBD patients has not been studied. Corticosteroids are
known to decrease CD4+ counts after acute administration,
which may be a consequence of re-distribution of leukocytes.
Chronic corticosteroid administration has a lesser effect.62
Nevertheless, corticosteroids are used as adjunctive therapy
in the treatment of complications of HIV infections such as
lymphoma or Pneumocystis jiroveci infection.63 A single
centre study investigated the effects of 40 mg/day pre-
dnisolone as an adjunct to antiretroviral therapy in 24 HIV-
infected subjects with N200 CD4+ T cells/mm3 in a ran-
domized placebo-controlled trial. After 8 weeks, no effect
was observed on markers of T-cell activation or apoptosis.
Two subjects assigned to prednisolone were subsequently
found to have asymptomatic osteonecrosis of the hip. The
authors concluded that the potential role of corticosteroids
as adjunct therapy will be limited by concerns regarding
their toxicity; however, further studies of other agents to
limit cellular activation in AIDS are warranted.64 It is reason-
able to use corticosteroids for the therapy of IBD patients
with HIV infection receiving HAART who have achieved
immune reconstitution and undetectable viral loads, but no
data are available.
Azathioprine and its effect on HIV infection in IBD patients
have also not been evaluated. Anecdotal evidence suggests
that treatment with azathioprine leads to exacerbation of
HIV disease and should be avoided.65 However, there is one
case report describing long-term non-progressive HIV-1
infection and excellent graft survival in a patient after
renal transplantation receiving a conventional immunosup-
pressive regimen, namely azathioprine and prednisolone.66
No data on the use of azathioprine in patients with IBD and
active or successfully treated HIV infection are available, so
as with steroids, carefully monitored treatment is appro-
priate if necessitated by the clinical pattern of IBD.
TNF-α has been implicated in the pathogenesis of HIV
infection, by contributing to HIV replication through activa-
tion of NF-кB.67 Increased TNF-α concentrations have also
been associated with advanced stages of HIV infection and
the occurrence of infectious complications. It has also been
proposed that increased circulating TNF-α, interpreted as a
reflection of a frustrated immune response unable to con-
trol HIV,68 may even accelerate the disease.69 There are,
however some studies on the effects of anti-TNF-α therapy
on the course of HIV infection which have been reviewed.70
These small studies of 6–11 patients have indicated that
neither infliximab nor etanercept in single (etanercept) ordouble doses (infliximab 10 mg/kg two weeks apart)
worsened HIV infection. A third study investigated the effect
of a four week therapy with etanercept (25 mg twice weekly)
in 16 untreated HIV patients with smear positive tuberculosis
and CD4+ cells N200/mm3. The clinical response to anti-
tuberculous chemotherapy was at equivalent or superior to a
historical treatment group,71 although it is difficult to re-
commend such a high-risk strategy. These data suggest that
anti-TNF therapy may be given to IBD patients with co-
existing HIV infection and might not have the detrimental
effects on HIV infection that theory might suggest.72
3.3.3. Preventive measures
General measures to prevent HIV infection are appro-
priate. These include educational initiatives to avoid sexual
transmission by using condoms and avoiding shared needles
in intravenous drug users. Post-exposure prophylaxis is
appropriate for health professionals exposed to contami-
nated injection needles or blood from HIV-positive indivi-
duals. Local guidelines are likely to be available and
specialist advice is appropriate.
3.3.4. Diagnostic approach, screening and treatment of
the underlying infection
Diagnostic approach and screening
All IBD patients undergoing immunomodulator or biologi-
cal therapy are best tested for HIV infection (through HIV
p24 antigen and antibody testing, with PCR only if acute
infection is suspected) to rule out active infection,
because of the potential consequence of such therapy
should HIV be acquired. It is reasonable to take the risk of
acquiring HIV into account.
Treatment of the infection
Due to the lack of clinical data on the effect of immune-
reconstitution following treatment with HAART on the
course of concomitant HIV and IBD, no recommendations
are available.70 It is reasonable to assume that HAARTwill
control viral replication and induce immune reconstitu-
tion, so that HIV-infected IBD patients will have fewer
infectious complications from immunosuppressive IBD
therapy than if they did not receive HAART. However,
the different immunopathology of Crohn's disease and
ulcerative colitis may mean that the effects and benefits
of HAART on the underlying IBD may also differ.
The susceptibility to infection of IBD patients suffering
from HIV greatly depends on the success of HAART. When
the CD4+ count is N350/µl the risk may be little different
to those without HIV. However, potential interactions
between immunomodulators and HAART, apart from
possible modification of the success of HAART, are largely
unknown. There may be cumulative, additive, synergis-
tic, or antagonistic effects of the different drugs in terms
of pharmacokinetics, pharmacodynamics, or side effects
(www.hiv-druginteractions.org).
3.3.5. Infection occurring during immunomodulator
therapy
There are no reports of acute HIV infections during
immunomodulator or biological therapy. From a practical
point of view, symptomatic HIV infection should be treated
according to current guidelines. Interruption of immunomo-
dulator or biological therapy should be considered if there is
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increase in CD4+ count).
4. Herpesviruses (HSV, VZV, EBV, CMV), human
papilloma virus, JC virus and influenza virus
4.1. Cytomegalovirus (CMV) infectionECCO statement OI 4A
Screening for a latent or subclinical CMV infection
is not necessary before starting immunomodulator
therapy [EL2, RG B]. Latent or subclinical CMV
infection is no contraindication for an immunomo-
dulator therapy [EL2, RG B]. CMV colitis should be
excluded, preferably by tissue PCR or immunohis-
tochemistry, in immunomodulatory refractory
cases of IBD before increasing immunomodulator
therapy [EL3, RG C]. In case of severe colitis with
CMV detected in the mucosa during immunomo-
dulator therapy, antiviral therapy should be
initiated and discontinuation of immunomodula-
tors considered until colitis symptoms improve. In
case of systemic CMV infection immunomodulator
therapy must be discontinued [EL2, RG B]4.1.1. Background
The majority of primary infections with CMV are asympto-
matic. Clinically apparent infections may present as a mono-
nucleosis-like syndrome, but can affect virtually any organ.73,74
Although CMV may persist in a latent form after primary
infection, development of severe CMV-related disease during
or after immunosuppressive therapy is rare in IBD. There is,
however, a risk of hepatitis, colitis, oesophagitis, pneumonia,
encephalitis or retinitis.73–75 Although CMV has a world-wide
distribution, the prevalence of CMV is higher in developing
countries, or areas with poor socioeconomic conditions. This is
probably related to closer physical contact, since CMV is trans-
mitted via close personal contact with affected persons
excreting the virus in their body fluids, or shedding from throat
or uterine cervix.74 10–20% of children are infected with
CMV before puberty and CMV seroprevalence increases after
infancy to 40–100% in adults.74,76 CMV colitis mimicking an
acute exacerbation of ulcerative colitis (UC) or Crohn's disease
(CD) is associated with a poor outcome and a higher colectomy
rate.77–79
4.1.2. Impact of immunomodulator therapy on natural
history of the disease
Immunomodulator therapy is often associated with sub-
clinical reactivation of latent CMV infection.80 This reactiva-
tion is usually asymptomatic, or characterised by a mild,
self-limited course. Serious tissue damage is very rare.73,81 It
is appropriate to draw a distinction between CMV infection
(detectable by serology or viral DNA), and CMV disease (such
as colitis, causing end-organ damage).
Several studies have suggested an association between
infection with CMV and steroid- or therapy-resistant IBD andcomplications, including toxic megacolon.78,82–91 A causal
relationship, however, has not been proven. CMV infection is
common in immunocompromised patients with IBD, but not
all CMV infections lead to clinical disease.92 Matsuoka has
demonstrated that CMV is frequently reactivated in patients
with UC treated with steroids or 6-mercatopurine, but
disappears without antiviral therapy.93 In their series, CMV
antigen concentrations were low in all patients and none had
clinical symptoms or CMV detected in biopsy specimens.
These data agree with previous studies showing that
subclinical reactivation of CMV during immunomodulator or
biological therapy is common, but nearly always self-limited
even if therapy is continued.94–96 Consequently, with the
exception of severe infection (see below), immunomodula-
tor treatment may be continued during CMV reactivation.
4.1.3. Preventive measures
There is no CMV vaccine available. Although different
nucleoside analogues are effective therapy for severe CMV
infection, the potential for adverse events does not justify
standard chemoprophylaxis.73,74,80
4.1.4. Diagnostic approach, screening and treatment of
the underlying infection
Diagnostic approach and screening
Only a minority of CMV infections lead to clinical disease,
so screening for subclinical CMV infection in IBD patients is
not indicated. Different techniques for the diagnosis of
CMV infection are available (Table 1). The high seropre-
valence in the adult population means that serology is of
limited value for the diagnosis of active infection, but
detection of CMV-specific antibodies can be used to
diagnose recent infection (CMV IgM, change in IgG
concentration, or IgG avidity). This identifies patients at
risk from CMV reactivation (CMV IgG).74,76,97 Conventional
viral culture and the faster shell vial culture are highly
specific, but have disadvantages including long incuba-
tion, lack of viral quantitation, false-negative results if
cell culture inoculation is delayed, and lower sensitivity
compared to antigenaemia assays or PCR. CMV antige-
naemia assays are only semiquantitative, but act as an
indirect marker of disseminated infection. They are suf-
ficiently rapid to monitor infection and antiviral treat-
ment in immunocompromised patients, if measurement
of viral load by PCR is not readily available.74,97 The most
commonly used technique for diagnosis of CMV infection
and disease is detection of CMV DNA through PCR. The
advantages of PCR are rapid results, high sensitivity, the
potential for qualitative and quantitative testing, detec-
tion in a wide range of samples (whole blood, buffy coat
specimens, bronchoalveolar lavage (BAL) fluid, stool) and
applicability in neutropenic patients.74,76,97
In patients with severe colitis, CMV has been reported
in colonic tissue in 21–34% and in 33–36% of steroid-
refractory colitis.80 Histopathology combined with
immunohistochemistry (IHC, using monoclonal antibodies
against CMV immediate early antigen) are highly spe-
cific and sensitive for verifying CMV infection in tissue or
biopsies.
Treatment of the infection
Ganciclovir (for 2–3 weeks) is the therapy of choice
for CMV infections. After 3–5 days, a switch to oral
Table 1 Sensitivity and specificity of different techniques
for diagnosis of CMV infection.80
Method Sensitivity
(%)
Specificity
(%)
Histology H&E staining 10–87 92–100
Immunohistochemistry 78–93 92–100
Serology CMV IgM 100 99
CMV IgG 98–100 96–99
Viral culture Conventional 45–78 89–100
Shell vial culture 68–100 89–100
Antigenaemia
assay
60–100 83–100
DNA tests PCR 65–100 40–100
58 J.F. Rahier et al.valganciclovir for the rest of the 2- to 3-week course may
be considered if available, depending on the clinical
course and local specialist advice.80,81 In cases of
ganciclovir resistance or intolerance (e.g. myelotoxicity),
foscarnet (for 2–3 weeks) is an alternative.80,81,98
4.1.5. Infection occurring during immunomodulator therapy
Subclinical or mildly symptomatic reactivation does not
require treatment or interruption of immunomodulator
therapy and usually passes unrecognised. Severe, systemic
CMV reactivation causing meningo-encephalitis, pneumoni-
tis, hepatitis, oesophagitis, or colitis, is rare, but associated
with a poor outcome.77,79,80 Prompt antiviral treatment with
ganciclovir or other agents and discontinuation of immuno-
suppressive agents is associated with clinical improvement
and decreased mortality,77–80 so are recommended.
4.2. Herpes simplex virus (HSV)ECCO statement OI 4B
Screening for latent HSV infection or chemopro-
phylaxis before onset of immunomodulator ther-
apy is unnecessary [EL2, RG B]. Past or latent HSV
infection is no contraindication to immunomodu-
lator therapy [EL2, RG B]. In case of recurrent
labial or genital HSV infection, oral antiviral
therapy should be considered during immunomo-
dulator therapy [EL2, RG C]. HSV colitis is best
excluded by immunohistochemistry or tissue PCR
as a cause of immunomodulatory refractory IBD
before increasing immunomodulator therapy
[EL4, RG D]. In the event of severe HSV during
immunomodulator therapy, antiviral therapy
should be initiated and immunomodulators dis-
continued till improvement of symptoms [EL4,
RG C]4.2.1. Background
Primary infection with HSV in immunocompetent indivi-
duals usually causes an asymptomatic or mild, self-limitedoral–labial (generally HSV type 1) or genital (generally HSV
type 2) infection, followed by latent HSV persistence in nerve
ganglia.75,99 Seroprevalence for Herpes simplex virus type 1
(HSV-1) and type 2 (HSV-2) depends on different factors
including age, gender, country, region within the country and
population subgroup. The worldwide prevalence of HSV-1 by
the fourth decade is 45–98%.99 HSV-2 seroprevalence
correlates with age and gender (higher in women), rising
with initiation of sexual activity in adolescence and increas-
ing through adulthood.100 It is negligible under the age of
12 years, increases to a peak between 15 and 24 years of age
and declines with advanced age.
4.2.2. Impact of immunomodulator therapy on natural
history of the disease
In immunocompromised individuals HSV infections have a
greater potential for dissemination.75 HSV reactivation may
cause severe systemic infections associated with significant
morbidity and mortality including encephalitis, meningitis,
pneumonia, oesophagitis, colitis, or hepatitis.101–106 Cell-
mediated immunity appears to be the dominant process for
controlling viral replication.100 Recurrent oral or genital
herpes may be both more frequent and severe in immuno-
compromised patients.107
4.2.3. Preventive measures
There is no vaccine available for HSV. Chemoprophylaxis
for HSV infection is unnecessary for the same reasons as CMV
(Section 4.1.3). In the event of recurrent labial or genital
HSV infection, oral antiviral therapy should be considered:
aciclovir 400 mg twice daily, valaciclovir 500 mg daily, or
famciclovir 250 mg twice daily are appropriate.108
4.2.4. Diagnostic approach, screening and treatment of
the underlying infection
Diagnostic approach and screening
The presence of high titres of anti-HSV IgG in the serum,
the appearance of HSV-specific IgM, or increasing titres of
anti-HSV IgG, are indicators of relapsing HSV infection,
but only few patients with recurrent HSV infection show
a large increase in the HSV antibody titre. Serologic
detection of HSV antibodies indicates prior exposure to
HSV, but is inadequate for diagnosis. The diagnostic gold
standards for HSV infection is PCR or IHC from affected
tissue or biopsies.99 Screening for latent HSV-infection in
IBD patient is not indicated.
Treatment of the infection
The nucleoside analogue aciclovir is effective ther-
apy.75,107 Aciclovir selectively inhibits the replication of
herpesviruses by inhibiting the viral polymerase after
intracellular uptake and conversion to aciclovir tripho-
sphate.109 Other antiviral drugs for the treatment of HSV
infection are valaciclovir, a prodrug of aciclovir, penci-
clovir, or its prodrug famciclovir.75,107
4.2.5. Infection occurring during immunomodulator
therapy
Since most cases of systemic HSV reactivation in immuno-
compromised patients are subclinical or run amild, self-limited
course, they do not require discontinuation of immuno-
modulators or systemic antiviral therapy.110 Nevertheless,
immunomodulators should not be initiated during active
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immunosuppressive therapy.75 Thought should be given to the
potential for disseminated HSV infection when considering
azathioprine in a patient with active labial or genital HSV.
Severe HSV infection causing hepatitis,101,104,111 encephali-
tis,112 colitis,102,106,111,113 or pneumonitis104,114 during immu-
nosuppressive therapy for IBD are extremely rare. Antiviral
therapy with intravenous aciclovir or alternative (Section
4.2.4) and discontinuation of immunosuppressants are appro-
priate.102,106,113 HSV colitis is very rare even in patients with
IBD, but it might cause or mimic an acute relapse.102,106,111,113
The risk of colectomy is high.1064.3. Varicella zoster virus (VZV)ECCO statement OI 4C
If the medical history of chickenpox, shingles and
VZV vaccination is negative, immunisation with
VZV vaccine should be performed at least
3 weeks before onset of immunomodulator
therapy, and preferably at diagnosis of IBD
[EL5, RG D]. Previous VZV infection is not a
contraindication to immunomodulator therapy,
but should not be started during active infection
with chickenpox or herpes zoster [EL4, RG D]. In
the event of VZV infection during immunomodu-
lator therapy, antiviral treatment should be
started [EL1, RG B] and immunomodulator
therapy discontinued in severe cases if possible
[EL5, RG D]. Reintroduction of IM therapy is
possible after vesicles and fever have resolved
[EL5, RG D]
4.3.1. Background
Unlike other herpesviruses, primary infection with VZV is
nearly always symptomatic. It causes chickenpox (varicella),
characterised by fever, malaise and typical vesicular skin
lesions115 and after reactivation of latent VZV in dorsal root
ganglia, herpes zoster (shingles) may develop. In the pre-
vaccine era almost all children became infected by the age
of 15 years.
4.3.2. Impact of immunomodulator therapy on the natural
history of the disease
Reactivation of VZV is mainly found in patients aged
N50 years or immunocompromised patients. It typically
manifests as a painful, unilateral, vesicular rash distri-
buted in one or more dermatomes. Immunosuppression
increases the risk of dissemination and complications such
as pneumonia, hepatitis, encephalitis, or haemorrhagic
disorders (thrombocytopenia or disseminated intravascular
coagulopathy).115,116
4.3.3. Preventive measures
For children with IBD not on immunomodulator therapy,
recommendations for immunisation are the same as the
general population.117 Depending on local guidelines, rou-
tine live-virus VZV vaccination is given at the age of 12–18 months with a booster at 11–12 years of age.115–118 For
immunocompromised children, including those on high-
dose corticosteroids (14 day course of prednisolone
N2 mg/kg pr (or equivalent), or a total of ≥20 mg pred-
nisolone/day for children with a weight N10 kg), live-virus
vaccine is contraindicated until immunomodulators have
been discontinued for at least 3 months.118
Unimmunised, immunocompetent adults with IBD should
best receive active immunisation with a 2-dose series of live
varicella vaccine at least 3 weeks before immunomodulators
are started.115,118
Passive immunisation with a high-titre preparation of
VZV IgG antibodies (VZIG) is appropriate for unimmunised,
seronegative, high-risk patients with IBD (immunosup-
pression, pregnancy) who have had close exposure to a
person with chicken pox or herpes zoster. VZIG should be
given within 96 h of exposure in a recommended dose
(125 units, or 1 vial/10 kg of body weight to a maximum
625 units).115,117,118 After administration of VZIG, patients
should be observed for 28 days. In the event of clinical
symptoms of VZV infection, immediate antiviral therapy
should be initiated118 although specialist advice is best
taken.
4.3.4. Diagnostic approach, screening and treatment of
the underlying infection
Diagnostic approach and screening
VZV has a worldwide distribution, with a preference for
temperate climates, where seroprevalence is N90% in
adults.115 Serology is of limited value for the diagnosis of
acute VZV infection, because testing for VZV IgM and IgG
antibodies lack specificity and sensitivity.115 Neverthe-
less, detection of VZV IgG antibodies reliably determines
former VZV infection if a history of varicella is unknown or
uncertain. PCR, viral culture and IHC or hybridization
methods are more sensitive for confirming a diagnosis of
current VZV infection or reactivation if there is clinical
uncertainty.115,116
Treatment of the infection
Aciclovir for chickenpox and zoster and valaciclovir or
famciclovir for zoster are licensed antiviral agents.
Alternatives in aciclovir-resistant cases are foscarnet.115
4.3.5. Infection occurring during immunomodulator
therapy
Primary infection or reactivation of VZV during immuno-
modulator therapy leading to chickenpox or herpes zoster is
uncommon.26,110,119–124 Immunomodulators should not be
initiated during chickenpox or shingles. Recurrent herpes
zoster, depending on the severity or frequency, is a relative
contraindication to immunomodulators.115
Only a few cases of severe varicella or herpes zoster
associated with immunomodulators in IBD or rheumatoid
arthritis have been reported, but most experienced
clinicians have seen or heard of a case. However,
disseminated VZV should be considered a medical emer-
gency and treated as soon as possible. Except for 3 fatal
cases,125–127 all patients recovered after intravenous
antiviral therapy with aciclovir. In some cases, immunomo-
dulators were temporarily discontinued121,128–138 until
improvement of clinical symptoms, then restarted without
further problems.
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Screening for latent or subclinical EBV infection or
chemoprophylaxis before onset of immunomodu-
lator therapy is not recommended [EL2a, RG B].
In severe clinical EBV infection during immuno-
modulator therapy, antiviral therapy should be
initiated and immunomodulator therapy discon-
tinued [EL4, RG D]. In the event of EBV-related
lymphoma during immunomodulator therapy,
immunomodu- lators should be stopped, because
discontinuation of immunomodulators often leads
to spontaneous regression. In case of absent spon-
taneous regression or progression of lymphoma
after interruption of immunomodulators chemo-
therapy should be considered [EL4,RGD]4.4.1. Background
Like other members of the herpesvirus family, EBV infects
more than 90% of the world's adult population, regardless of
geographical location. EBV seropositivity increases with age
(N96% when over 60 years of age).139–141 Primary EBV infec-
tion is often asymptomatic, or causes infectious mononu-
cleosis, which usually takes a mild and self-limiting course.
After primary infection EBV remains latent in circulating B
lymphocytes for life.139–141
4.4.2. Impact of immunomodulator therapy on the natural
history of the disease
EBV infection has been associated with the development
of neoplasia, including lymphoma, sarcoma and carcinoma,
especially in those who are immunocompromised.142 Several
studies have shown the potential for self-limited reactivation
of latent EBV infection after introduction of immunomodu-
lators, without provoking symptoms or serious EBV-asso-
ciated disease.95,96,143,144 Nevertheless, some data suggest
that even a transient increase in EBV DNA load may increase
risk of lymphoma.95,144 An EBV load of N1000 copies per
500 ng DNA of peripheral blood mononuclear cells (PBMCs)
seems to be associated with an increased risk of lymphopro-
liferative disorders in heart transplant patients.143
4.4.3. Preventive measures
No EBV vaccine is available. Chemoprophylaxis is not
recommended, because reactivation during the treatment
of IBD leading to serious clinical disease is exceptionally
rare.
4.4.4. Diagnostic approach, screening and treatment of
the underlying infection
Diagnostic approach and screening
Serological diagnosis of EBV infection use direct immu-
nofluorescence against IgG or IgM antibodies targeting
EBV capsid antigen (VCA), as well as IgG antibodies spe-
cific for EBV nuclear antigen 1 (EBNA 1). Primary EBV
infection is confirmed by detection of VCA IgM in theabsence of EBNA 1 IgG. Recent EBV infection is detected
by EBNA 1 IgG without VCA IgM. However, VCA IgM anti-
bodies may be undetectable, or their appearance may
be delayed during active infection. Diagnosis is further
complicated because VCA IgM may persist for several
months after infection. Therefore RT-PCR is both more
reliable and more sensitive for early, definitive diagnosis
of EBV, especially in serologically indeterminate EBV
infections.145,146
Treatment of the infection
In most cases EBV infection does not require antiviral
treatment and in normal people the clinical benefit of
antiviral therapy for infectious mononucleosis has not
been established.147 In the event of severe EBV-
associated disease, therapy with aciclovir or ganciclovir
may be given, but efficacy against EBV is not as high
as for CMV, HSV or VZV.75,148 Specialist advice is
appropriate.
4.4.5. Infection occurring during immunomodulator
therapy
Only two cases of fatal infectious mononucleosis
after primary EBV infection associated with azathioprine
therapy in patients with Crohn's disease (CD) have been
reported.149,150 When severe EBV-associated disease occurs
in immunocompromised patients, antiviral therapy with
aciclovir or ganciclovir is best initiated promptly, despite
the lesser efficacy compared to other herpesviruses. It is
possible that ganciclovir is more potent than aciclovir for EBV
infection and may help prevent lymphoproliferative dis-
orders, but further data are necessary.148
A higher rate of lymphoma has been reported in patients
with IBD, especially if treated with immunomodulators,
compared to the general population.151,152–169 In transplant
recipients, a viral load of N1000 copies of EBV per 500 ng DNA
from PBMCs may be a marker for an increased risk of EBV-
associated lymphoproliferative disorders.143 Discontinuation
of immunosuppressive therapy often results in spontaneous
regression of EBV-associated lymphoma.157,165 Prophylaxis
with aciclovir or ganciclovir after renal transplantation has
been reported to reduce the risk of lymphoma in renal
transplant recipients,148 but the risk of lymphoma is too low
to justify this approach in IBD.
4.5. Human papilloma virus (HPV)ECCO statement OI 4E
Regular gynaecologic screening for cervical cancer
is strongly recommended for women with IBD,
especially if treated with immunomodulators
[EL2a, RG B]. In patients with extensive cutaneous
warts and/or condylomata, discontinuation of
immunomodulator therapy should be considered
[EL5, RG D]. Routine prophylactic HPV vaccination
is recommended for women according to national
guidelines [EL2a, RG B]. Current or past infection
with HPV is no contraindication for immunomodu-
lator therapy [EL2a, RG B]
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Human papillomavirus (HPV) is the most common sexually
transmitted infection in the world.170 The distribution varies
widely, depending on gender (higher in women than in men),
geographical region (higher in poor countries), age, sexual
behaviour and viral type, as well as the methods and site of
detection.171,172 About 40 types of HPV are sexually trans-
mitted. They are classified into low-risk types, associatedwith
anogenital warts or mild dysplasia, and high-risk types
associated with high-grade dysplasia and anal neoplasia
(cervical and anal carcinoma).173,174 Cutaneous warts are
also caused by HPV.
4.5.2. Impact of immunomodulator therapy on natural
history on the disease
Immunomodulators do not generally aggravate the course
of the disease, but there is concern that HPV-associated
tumors may be more common after years of immunomodu-
lator therapy.
4.5.3. Preventive measures
Since 2006 a prophylactic quadrivalent vaccine (Garda-
sil®, Silgard®) using L1 virus-like particles (VLP) of HPV-6, -11,
-16 and -18 is available in Europe. In 2007, a bivalent vaccine
(Cervarix®) containing L1 VLPs of HPV-16 and -18 was
approved in Europe. Both vaccines are highly immunogenic,
safe and offer high protection (95–100%) against HPV
infection in immunocompetent patients.175,176
Depending on local guidelines, routine HPV vaccination is
recommended for females aged 11–12 years before onset of
sexual activity. In the event of missed or delayed vaccina-
tion, HPV vaccination is also recommended for females aged
13–18 years. It is not recommended for males, females aged
younger than 9 years, or older than 26 years because the
efficacy, safety and cost-effectiveness of HPV vaccination in
these cohorts has not been established.177–181 HPV immuni-
sation uses a non-live agent, so it may be administered to
immunocompromised IBD patients.117
4.5.4. Diagnostic approach, screening and treatment of
the underlying infection
Diagnostic approach and screening
Measurement of serum antibodies (IgG and IgA) to
type-specific virus-like particles (VLPs) or capsids is a
useful marker of prevalent or persistent HPV exposure
and reflects infection whatever the anatomical site.
Such antibodies are inadequate for diagnosis of HPV
infection, because not all patients seroconvert after
HPV exposure and HPV antibodies can take a year or
more to appear.182,183 Identification of HPV DNA via
PCR is specific for diagnosis of a HPV infection, but
since HPV infection is transient and usually clears
within 2 years, it is limited to the detection of current
infection.184
Cervical smear testing in immunocompromised women is
recommended as for the general population.185,186 A
practical point is to ask female patients on immunomo-
dulators whether they have had a cervical smear. HPV
screening is not recommended for men in the general
population, because there is currently no evidence that
screening or treatment reduces the risk of progression to
(anal) cancer in this group.170Treatment of the infection
No antiviral agents for eradicating or treating of HPV in-
fections are known. Treatment options for HPV-associated
carcinoma include surgery, chemo- and radiotherapy.185,187
4.5.5. Infection occurring during immunomodulator
therapy
Two studies describe a higher prevalence of abnormal
cervical (‘Pap’) smears associated with HPV-16 and -18 in
women with IBD compared to the general population. The
risk of an abnormal smear associated with HPV-16 and -18 has
also been reported to increase in patients on immunomodu-
lator therapy.188,189 Therefore women with IBD and espe-
cially those on immunomodulators are best advised to have
regularly screening as high risk patients according to local or
ACOG guidelines.190 They may be considered candidates
for HPV vaccine regardless of their sexual history.188,189
Nevertheless, infection with HPV is no contraindication to
immunosuppression.
Anal carcinoma and squamous cell carcinoma (SCC) in
particular are considered to rare complications of IBD (perhaps
more common in thosewith chronic fistulating Crohn's disease)
and may be associated with infection with carcinogenic types
of HPV.187 There are reports of an increased frequency of
anogenital warts in immunocompromised patients.191 Discon-
tinuation of immunomodulators may be helpful in patients
with extensive anogenital warts. Infection with HPV while on
immunomodulators does not otherwise present a clinical
problem, although there are occasional cases of disseminated
cutaneous warts in patients who have been on azathioprine
for years. Treatment is best conducted with a dermatologist,
but the risk of exacerbating the underlying IBD by withdraw-
ing azathioprine has to be considered and discussed with the
patient.
4.6. JC virusECCO Statement OI 4F
Progressivemultifocal leukoencephalopathy (PML)
is caused by reactivation of JC viral infection,
which is latently present in 60–80% of adult
Europeans. Specific screening recommendations
for the risk of PML cannot be issued at present, but
prescribing physicians should be aware of the
disease [EL5, RG D]
ECCO Statement OI 4G
Patients with profound medical immuno-suppres-
sion, specifically those with anti α4 integrin
therapy, and with new onset neurological symp-
toms should receive a contrast enhanced MRI of
the brain and lumbar puncture for CSF analysis of
JC viral load to detect PML [EL5, RG D]
4.6.1. Background
Progressive multifocal leukoencephalopathy (PML), is a
rare but usually fatal opportunistic brain infection caused
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has become more common in the HIV/AIDS pandemic.
Polyoma virus infection is ubiquitous in Europe, most
commonly at young age and usually remains dormant for
life. When three cases of PML in patients with multiple
sclerosis (MS) and Crohn's disease (CD) were linked to
treatment with the anti-α4 integrin antibody natalizumab,
the commercial and investigational use of leucocyte
trafficking inhibitors directed at α4 integrins was sus-
pended (February 2005). Natalizumab therapy was subse-
quently resumed for multiple sclerosis192–194 and for CD in
the US, but it has as yet been denied a European licence for
CD. An FDA warning (2008) about an increased risk of PML
among patients treated with monoclonal anti-CD20 anti-
bodies was issued after two patients with systemic lupus
erythematosus treated with rituximab died of PML,
illustrating the necessity of increased vigilance for other
therapeutic antibodies.195,196
4.6.2. Impact of immunomodulator therapy on natural
history on the disease
Reactivation of JC virus in the brain results in demyelina-
tion, giant astrocytosis and destruction of glial cells. PML is
clearly associated with profound immune suppression
such as AIDS, organ transplantation and haematological
malignancy.
4.6.3. Preventive measures
Because of the risk of PML, natalizumab is available for MS
only through a restricted distribution programme called
theTOUCH™PrescribingProgram (see: http://www.fda.gov/
bbs/topics/NEWS/2006/NEW01380.html, http://www.
emea.europa.eu/humandocs/Humans/EPAR/tysabri/
tysabri.htm; http://www.fda.gov/bbs/topics/NEWS/2008/
NEW01775.html,). A similar programme has become avail-
able for CD in the US, restricting its use to patients who have
refractory disease after failing both immunomodulators and
anti-TNF agents. Withdrawal of other immunomodulators,
screening for and subsequent monitoring JC virus infection is
mandatory. There have now been N20000 patient-treatment
years and (as of Q1 2009), at least two further cases of PML
associated with natalizumab have been reported. The risk for
individuals during extended treatment (N2 years) remains to
be established.
4.6.4. Diagnostic approach, screening and treatment of
the underlying infection
Anti-adhesion molecule therapy offer major promise for
the prevention of relapse of MS and CD, but the currently
estimated 1/1500 risk of PML in patients exposed to
natalizumab and the lack of adequate therapy for PML,
calls for reliable screening strategies.197,198 Nevertheless,
whether JC viral load assessments in blood, urine, or
cerebrospinal fluid (CSF) can predict the risk of PML is
debated and needs further study. Patients with medically-
induced immunosuppression, specifically with anti-integrin
therapy, should be closely monitored for new neurological
symptoms such as lethargy or personality change, and the
appearance of neurological signs should prompt a contrast-
enhanced cranial MRI and referral to an infectious disease
specialist or neurologist for consideration of lumbar punc-
ture to assess CSF JC viral load.4.6.5. Infection occurring during immunomodulator
therapy
No single therapy has demonstrated efficacy for the
treatment of PML as a consequence of JC virus reactivation
in the brain. Controlled clinical trials with antiviral or
cytotoxic agents including interferon-a2b, cytarabine,
cidofovir and topotecan have been negative.199 Since
PML almost exclusively occurs in immunocompromised
patients, any effort to overcome the immunosuppression
should be considered. Immunomodulators should be dis-
continued immediately. Expert opinion from a neurologist
or infectious disease specialist experienced in the manage-
ment of patients with PML should be sought. Case reports,
including a patient with multiple sclerosis treated with
natalizumab, have suggested benefit of cytarabine for five
days.193,200 For patients with inflammatory forms of PML
identified by MRI and neurologic deterioration, high dose
intravenous glucocorticosteroids may be considered to
decrease cerebral oedema, although steroids will increase
immunosuppression.4.7. Influenza virusECCO Statement OI 4H
Patients on immunomodulator therapy are con-
sidered to carry an enhanced risk for the devel-
opment of influenza infections [EL4, RG C]ECCO Statement OI 4I
An effective strategy to prevent influenza infec-
tions consists of annual vaccination with trivalent
inactivated influenza vaccine [EL1a, RG A].
Routine influenza vaccination of all patients with
inflammatory bowel disease on immunomodula-
tors is recommended [EL2, RG B]. The live
attenuated vaccine is not recommended. Vaccina-
tion appears not to have an impact on the activity
of inflammatory bowel disease [EL4, RG D].
Seroconversion after influenza vaccine is not
reduced by corticosteroids, methotrexate or
anti-TNF therapy, nor by dual therapy with these
agents, so monitoring the serological response is
not warranted [EL2a, RG B]. Thiopurines or
ciclosporin reduce influenza vaccine seroconver-
sion rates [EL2a, RG B]
ECCO Statement OI 4J
Antiviral treatment in patients diagnosed early
with influenza during an epidemic should be con-
sidered. Prophylaxis should follow national guide-
lines [EL5, RG D]
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There are two types of influenza virus that cause human
epidemics: type A and type B. Influenza virus A is divided into
subtypes, of which H1N1 and H3N2 are circulating globally.201
Infection with influenza is associated with mortality,
depending on risk stratification.202
4.7.2. Impact of immunomodulator therapy on natural
history on the disease
No data exist on the incidence of influenza infection in
patients with IBD, but immunomodulator therapy is generally
considered to enhance the risk of influenza infection.201
4.7.3. Preventive measures
Vaccination
Annual vaccination is the most effective method for
preventing influenza virus infection and is therefore
recommended for patients on immunomodulators in
guidelines from the American Center for Disease Control
and Prevention.201 Two types of vaccines are available.
Live attenuated influenza vaccine (LAIV) should only be
used for healthy persons age 5–49 years, so is not recom-
mended for patients on immunomodulators. In contrast,
the trivalent inactivated influenza vaccine (TIV) may be
used for any person older than 6months, including those on
immunomodulators.201 Little is known about the adaptive
immune response to influenza vaccination in IBD patients,
whether or not on immunomodulators. In organ transplant
patients, several studies have shown that immunomodu-
lators diminish antibody development to influenza vacci-
nation, sometimes necessitating a two-dose vaccination
regimen.203–209 In patients with rheumatoid arthritis, anti-
TNFα treatment has been reported to reduce antibody
titres after influenza vaccination. A pediatric study in IBD
showed a similar reduction of protective antibody devel-
opment to influenza vaccination in patients on immuno-
modulators, without any influence on the activity of IBD.
210 However, the immune response remains sufficient to
warrant annual influenza vaccination.211–213 Based on risk
stratification for influenza infection, IBD patients on
immunomodulators are considered to be at risk and best
receive annual TIV vaccination.117 This preventive strat-
egy is uncommonly applied in IBD patients and proof of
benefit is circumstantial.214–216
Chemoprophylaxis
The drugs oseltamivir and amantadine both decrease the
risk of symptomatic infection, when given in the early
phase after contact with a patient with influenza. When
given to a people in an institution during an outbreak, it
reduced the extent and severity of the outbreak.217 Post-
exposure prophylaxis for household contacts is recom-
mended in Sweden and Germany.218
4.7.4. Diagnostic approach, screening and treatment of
the underlying infection
Diagnostic approach and screening
Influenza is characterised by the sudden onset of fever
with subsequent tracheobronchitis, although any upper
respiratory infection syndrome can occur. In most cases,
the diagnosis is based upon symptoms. Diagnostic tests for
influenza include viral culture, serology, rapid antigen
testing, reverse transcriptase-polymerase chain reaction(RT-PCR), and immunofluorescence assays. Influenza anti-
viral agents should only be used for treatment of acute
clinical symptoms compatible with influenza at a time
when public health agencies report that influenza is prev-
alent in the community, or when influenza is specifically
diagnosed by rapid antigen tests.
Treatment of the infection
Four antiviral agents with activity against influenza virus
are available: amantadine, rimantadine, zanamivir, and
oseltamivir. Resistance of influenza virus to amantadine
and rimantadine is appreciable, so these drugs are rarely
appropriate. When zanamivir or oseltamivir are started
within 48 h of the onset of symptoms, a reduction in fever
and cough from 1.5 days to 3 days has been demonstrated.
Significant differences compared to placebo were found
only in those treated within 36 h of onset for oseltamivir
and within 30 h of onset for zanamivir.219,220 Country-
specific European guidelines recommend antiviral ther-
apy for patients at high risk of complications, except
Germany where there is a strong recommendation to
treat all patients.218
4.7.5. Infection occurring during immunomodulator therapy
Management of immunomodulator therapy
No data are available on the use of antiviral drugs for
chemoprophylaxis or treatment of active influenza infec-
tion in patients with IBD, whether or not on immunomo-
dulators. It seems advisable for immunocompromised
patients to start antiviral therapy within 36 h of illness
in the event of active influenza infection during an
epidemic, in order to reduce risk of influenza-related
complications.201
5. Parasitic and fungal infection
5.1. BackgroundECCO Statement OI 5A
The risk of parasitic or fungal infection in inflam-
matory bowel disease has not been quantified.
Systemic infections are exceptional, but mortality
appears to be high [EL4, RG D]
Parasitic or fungal infections, like other opportunistic
infections, are a consequence of a generic rather than
disease- or therapy-specific risk among immunocompromised
individuals. As a consequence, recommendations are empiri-
cal, based on first principles, or clinical judgement rather
than a sound evidence-base. The infections considered in this
section are the parasites Toxoplasma gondii and Strongy-
loides stercoralis, and fungal infections with Aspergillus
spp., Candida spp., Cryptococcus neoformans, Histoplasma
capsulatum and P. jiroveci (formerly P. carinii). The results of
the systematic literature search are shown in Tables 2 and 3.
Most sources are case reports, with substantial reporting bias
relating to immunomodulator or biological therapy used to
treat IBD or rheumatoid arthritis. Reports are skewed by one
paper on granulomatous infectious disease associated with
anti-TNF therapy. This study used the Adverse Event Report-
ing System (AERS), which is a passive reporting system that
Table 2 Reports of parasitic infection.
Pathogen n Single, double, triple IMs Anti-TNF related CsA related Deaths References
Strongyloides stercoralis 3 S = 2 1/3 0/3 1 out of 3 outcomes 225
D = 1
Toxoplasma gondii 5 Unknown 5/5 0/5 Unknown 221
Legend: Single, double or triple IMs = concomitant therapy with one (S), two (D), or three (T) immunomodulators. CsA: ciclosporin.
64 J.F. Rahier et al.documents adverse reactions to medications in the US. The
difficulty with the data is that there is no denominator, so the
incidence of infection is unknown. Furthermore, it does not
report outcomes.221 Two additional studies report P.jiroveci
after infliximab therapy. The first is a review of 84 cases of P.
jiroveciwith data gleaned from AERS between 1998 and 2003
for patients with rheumatoid arthritis being treated with
infliximab. There are no denominators and no outcome
data.222 The second is a Japanese study223 reporting on 5000
patients receiving infliximab for rheumatoid arthritis. The
incidence of P.jiroveci in this population was 0.4%. Once
again, there are no outcome data.
As a consequence, the risk of parasitic and fungal
infections in inflammatory bowel disease cannot currently
be quantified. A report of 1169 patients who had all received
an anti-TNF therapy (GAIN (n=315) and CHARM (854)),
identified opportunistic infections in 2.4% of 1169 patients,
with all but one infection being non-systemic candidiasis.224
5.2. Impact of immunomodulator therapy on natural
history of the disease
Corticosteroids, ciclosporin, tacrolimus, mycophenolate
mofetil and anti-TNF therapy are. potent inhibitors of
microbial specific T cell function, potentiating opportunistic
infection with fungal species, S. stercoralis and a variety of
intracellular pathogens. Immunosuppression not only reduces
the threshold for infection, but also promotes dissemination
and may induce pyrogenic or other systemic physiological
responses. Pulmonary involvement is a feature with most
systemic infections and fungal or parasitic pneumonia are
potentially life threatening. Systemic cryptococcosis can
cause pneumonia, but more commonly causes meningitis,
sometimes without meningism.Table 3 Reports of fungal infection.
Pathogen n Single, double or
triple IMs
Anti
rela
Aspergillus spp 33 S=6 31/3
D or T=27
Candida spp 89 S, D or T
therapy unclear
65/8
Cryptococcus neoformans 17 S=4 14/1
D or T=12
Unknown=1
Histoplasma capsulatum 57 S or D or T
therapy unclear
57/5
Pneumocystis jiroveci (P. carinii) 139 S, D, T
therapy unclear
119/Consequently a high index of suspicion should accompany
any complaint of breathlessness, cough, or confusion in a
patient being treated with immunomodulators, with a low
threshold for performing a chest radiograph, CT scan or MRI
and lumbar puncture with specific diagnostic tests as
appropriate (Section 5.4, Table 5). Strongyloides hyperinfec-
tion with alveolar haemorrhage and disseminated disease is
more frequently reported in patients receiving high doses of
steroids or other immunomodulators. The diagnosis should
be suspected in any patient with pneumonia from an
endemic area. Early implementation of therapy (such as
parenteral ivermectin for disseminated strongyloidiasis) can
be life-saving. Diagnostic delays usually reflect the failure to
consider the possibility of systemic opportunistic infection
when signs are few in the early stages.
5.3. Preventive measures
5.3.1. Immunisation and chemoprophylaxis for parasitic
or fungal infections except P. jiroveciECCO Statement OI 5B
No vaccines exist for preventing fungal infection.
Environmental exposure should be avoided.
Primary chemoprophylaxis is currently not in-
dicated. Secondary chemoprophylaxis should
be discussed with an appropriate specialist
[EL5, RG D]
Fungi are found in soil or farm dust. Some appear ubiqui-
tous (Aspergillus spp., Candida spp.), while others are as-
sociated with animals (C. neoformans in pigeon droppings)-TNF
ted
CsA
related
Deaths References
3 4/33 5 out of 6 outcomes 226
27 outcomes unknown 221
227
9 0/89 Nil deaths reported but
38 outcomes unknown
13,221,228, 229
7 0/17 1 out of 5
known outcomes
221,230–234
12 outcomes unknown
7 0/57 3 out of 18 outcomes
39 unknown outcomes
2,13,221,235–238
139 4/139 2 of 5 known outcomes 227,228,239–245
134 unknown outcomes
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distributed in the southern United States or Central Africa.
Parasites are more commonly associated with endemic areas
and gastroenterologists should be aware of travel to, or
from, the tropics and the sub-tropics, where S. stercoralis is
patchily endemic. There are, however, no vaccines for fungal
or parasitic infections, so preventive measures depend on
making immunocompromised individuals aware of the risks
when travelling to endemic areas. General advice includes
avoiding farms, pigeon lofts, or an extended duration of stay.
This is, of course, not always possible, so a high index of
suspicion is appropriate when treating patients, either in-
habitants or travellers, from such areas. It is worth
considering that it may be inappropriate to translate Western
thresholds for treatment of IBD with immunomodulators to
residents of endemic areas.
5.3.2. Immunisation and chemoprophylaxis for P. jiroveciECCO Statement OI 5C
No vaccines exist for preventing P. jiroveci pneu-
monia. For those patients on triple immunomo-
dulators with one of these being a calcineurin
inhibitor or anti-TNF therapy, standard prophy-
laxis with co-trimoxazole is recommended if
tolerated [EL4, RG D]. For those on double
immunomodulators, with one of these being a
calcineurin inhibitor or anti-TNF therapy, a Con-
sensus could not be reached on the use of pro-
phylactic co-trimoxazole
There is no consistency in the approach to prophylaxis
against P. jiroveci in patients with IBD treated with im-
munomodulators, despite some suggested guidelines.246
That heavily immunosuppressed patients are at risk from
P. jiroveci is not in doubt, but most patients with IBD treated
with calcineurin inhibitors or infliximab are generally well
nourished, on concomitant immunomodulators for a rela-
tively short duration and are as much at risk from other
opportunistic infections. This is unlike patients with HIV or
those on immunomodulators after transplant surgery. A
surrogate marker of severe immuno-suppression in IBD
patients is lacking. Since neither the necessity nor benefit
has been established in IBD patients, recommendations from
the Consensus are based on expert opinion and experience
from other immunocompromised patients. A recent meta
analysis showed a 91% reduction of occurrence of PCP when
chemoprophylaxis with cotrimoxazole was administered in
patients with haemotological cancers or transplants.247
Patients with HIV disease and a CD4+ count b200/mL had
fewer infections with P. jiroveci when maintained on
cotrimoxazole.248 It is rare for patients to acquire P. jiroveci
when the CD4+ count is N200/mL. In another patient
population, 13 cases of PCP were diagnosed among 519
patients undergoing allogeneic haematopoietic stem cell
transplantation. Three of these were on prophylaxis, but
these patients had a very lowCD4+ count (median 131/μL).249
Consequently the Consensus took into account the sim-
plicity and general lack of toxicity of chemoprophylaxis withcotrimoxazole along with the high mortality of active in-
fection. Combinations of immunomodulators were con-
sidered particularly important. Participants were asked to
vote (Yes or No, Y/N) on whether they would advise primary
prophylaxis for patients on immunomodulator therapy.
Table 4 displays the results of voting about prophylaxis for
P. jiroveci by the Consensus. The infectious disease specia-
lists were unanimous in recommending prophylaxis for
patients with single, let alone double immunosuppression.
This no doubt reflects their experience on the conse-
quences and difficulty in treating P. jiroveci, which gastro-
enterologists see exceptionally rarely. In contrast, the
views of the gastroenterologists no doubt reflect their
experience on the frequent use of such agents without any
opportunistic infection, let alone infection with P. jiroveci.
It is for this reason that the votes are reported, since they
illustrate contrasting views. More research is urgently
needed to identifying immune parameters for defining at-
risk patients.
There are multiple regimen for primary chemoprophy-
laxis: Trimethoprim–sulphamethoxazole (TMP-SMZ) is the
prophylactic agent of choice with one one-strength tablet
daily (80–400 mg) or half-dose daily of a double strength
tablet (160–800 mg) or a double-strength tablet 3 times per
week.
General measures to prevent infection may well be as
important as chemoprophylaxis. These include the nutri-
tional state of the patient, dose, duration and combination
of immunomodulator therapy. In one 7 year follow up study
of patients treated with ciclosporin, 3/86 patients (3.5%)
died of opportunistic infections, but only 1 from P. jiroveci
and 2 of Aspergillus fumigatus pneumonia. Some of these
were treated with ciclosporin 8 mg/kg/day for up to
12 months.227 In another 7 year follow up study there were
no cases of P. jiroveci in 72 patients without chemoprophy-
laxis when the ciclosporin dose was limited to 5 mg/kg/day
to achieve serum concentrations of 200–400 ng/mL, as well
as limiting the duration to 3–6 months and introducing
azathioprine in the last 4 weeks of steroid and ciclosporin
therapy.2505.4. Diagnostic approach, screening and treatment
of the underlying infection
5.4.1. Diagnostic approach and screening
ECCO Statement OI 5D
Screening for parasitic or fungal infection prior to
immunomodulator therapy is generally considered
unnecessary [EL5, RG D]. Specialist advice is
appropriate for patients returning from endemic
areas
There is no evidence to support a general policy of
screening for parasitic or fungal infections prior to ini-
tiating immunomodulator or biological therapy. Patients
returning from endemic areas or a past history of parasitic
Table 4 Results of Consensus voting on indications for P jiroveci prophylaxis.
Clinical situation Recommendation for primary prophylaxis
(Yes/total voters)
Prednisolone N20 mg/day for over 3 months 4/22 (all 4 were infectious disease specialists)
Prednisolone N20 mg/day with azathioprine/mercaptopurine or methotrexate 4/22 (all 4 were infectious disease specialists)
Any immunomodulator with ciclosporin or infliximab 14/22
Triple immunosuppression 22/22
66 J.F. Rahier et al.or fungal infections represent special cases. In the case of
S. stercoralis, however, screening of patients with risk
factors is best performed, although no method is ideal. Risk
factors include sustained travel to, or residence in, ende-
mic areas such as the tropics, or the Appalachians in the US
(see also Section 8.6). Serologic testing is widely available
and sensitive, but not specific. Relying on stool studies
alone is inadequate and skin testing is experimental. Posi-
tive serology in a patient with a compatible clinical history
preparing to undergo steroid therapy may be considered
sufficient grounds for therapy (with an imidazole drug or
ivermectin). Specialist advice should be sought.ECCO Statement OI 5E
Clinicians should be alert to the possibility of
parasitic or fungal infections in patients with
inflammatory bowel disease who have unex-
plained symptoms, including fever, dyspnoea, or
confusion and who are generally immunocompro-
mised [EL5, RG D]5.4.2. Interpretation of diagnostic tests for non-specialists
Specialist advice is recommended on the approach and
interpretation of diagnostic tests. The succinct details below
and Table 5 are intended as a general guide for non-specialists.
S. stercoralis
Microscopic identification of larvae in stool or duodenal
fluid is the usual method of detection, but repeated samples
may be required due to poor sensitivity. Larvae may be
detected in sputum from patients with disseminated
strongyloidiasis. Serology is indicated when the organism
cannot be demonstrated by direct microscopy. Immunocom-
promised persons with disseminated strongyloidiasis usually
have detectable IgG antibodies. Cross-reactions in patientsTable 5 Summary of diagnostic approaches to parasitic and fung
Pathogen Culture Serology Molecular
Pneumocystis jiroveci − − +/−
Strongyloides stercoralis − + −
Toxoplasma gondii − + (+/−)
Candida spp. + (+/−) (+/−)
Aspergillus spp. + +
Histoplasma capsulatum + + (+/−)
Cryptococcus neoformans + − −with filariasis and other nematode infections may occur, so a
positive test warrants continuing efforts to establish a
parasitological diagnosis.
T. gondii
Detection of Toxoplasma-specific antibodies is the pri-
mary diagnostic method for a recent infection by T. gondii.
Initially, test for Toxoplasma-specific IgG antibodies. A posi-
tive Toxoplasma-specific IgG titre indicates infection with
the organism at some time. A negative IgM titre usually
excludes recent infection, but a positive IgM titre is difficult
to interpret because IgM antibodies may be detectable for as
long as 18 months after acute infection.The most common
clinical presentation of T. gondii infection among patients
immunocompromised patients is a focal encephalitis. Pa-
tients with T. gondii encephalitis are almost uniformly sero-
positive for anti-toxoplasma IgG antibodies. Anti-toxoplasma
IgM antibodies are usually absent. Definitive diagnosis of
T. gondii encephalitis (TE) requires a compatible clinical
syndrome; identification of one or more mass lesions by CTor
MRI; and detection of the organism in a clinical sample. For
TE, this requires a brain biopsy, which is most commonly
performed by a stereotactic CT-guided needle biopsy. Most
clinicians rely initially on an empiric diagnosis, which can be
established as an objective response, on the basis of clinical
and radiographic improvement, to specific anti-T. gondii
therapy in the absence of a likely alternative diagnosis. Brain
biopsy is reserved for patients failing to respond to specific
therapy.
Candida spp
The predominant organism is C. albicans (N60%) but there
is a trend towards non-albicans (C. glabrata, C. tropicalis,
C. parapsilosis). There are multiple direct and indirect
methods of diagnosing Candida infection. A positive culture
from a normally sterile body site is the gold standard.
Cultures from blood, CSF, joint aspirate or other sterile
surgical sites are generally diagnostic. Candida species will
grow in standard blood culture bottles. Culture from most
other sites cannot differentiate colonisation from infection,al infections.
Other
Direct visualisation/cytology
Direct visualisation/histology
Clinical context+radiology
Radiology+direct visualisation (histology)/antigen detection
Cytology/antigen detection
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culture-based detection methods are being investigated but
have not reached clinical use.
Aspergillus spp
Diagnosis is difficult, especially in the immunocompro-
mised. Bronchoalveolar lavage (BAL) is only 50% sensitive and
a definitive diagnosis may require invasive procedures or
biopsy. Infiltrates on chest CT or a ‘halo’ sign in the correct
clinical context is enough to commence therapy.
Non-culture based procedures include antigen or DNA
detection. Serum ELISA detecting galactomannan is FDA-
approved. Two positive ELISAs plus radiology plus clinical
scenario is interpreted as ‘probable invasive aspergillosis’.
Microbiological or histopathological demonstration of fun-
gal elements in body tissue or fluid is ideal, but not all
branching fungi are Aspergillus spp., so other moulds need
to be considered.
Histoplasma capsulatum
Most infections are identified as incidental findings on a
chest radiograph but this fungus can disseminate. Diagnosis is
made by culture, fungal stains of body fluids or tissues, or
tests for antibodies or antigens. Culture is frequently nega-
tive in mild cases. Histopathology is rapid, but only 50%
sensitive. Only a few yeast-forms may be present and can be
misidentified as other fungi, such as Candida spp., Penicillium
sp., or Pneumocystis sp.
Antibodies are detectable in 90% of patients after 2-6
weeks, but may not be present in immunosuppressed pa-
tients. A polysaccharide antigen is generally detectable in
body fluids such as urine, CSF, or BAL fluid. It is detectable
earlier than antibody serology or culture and has the poten-
tial to monitor therapy.
C. neoformans
Laboratory diagnosis is established by the isolation of the
organism in culture, histopathology, or detection of a poly-
saccharide capsular antigen. Analysis of CSF usually reveals a
low white cell count with a normal or low-CSF glucose
concentration and a positive cryptococcal antigen test. Crypto-
coccal antigen in the CSF (detected by latex agglutination) is
very reliable and may also be positive in plasma. The
cryptococcal antigen detection test is not useful for monitoring
the course of therapy.Table 6 General guidance for treating parasitic or fungal infecti
Pathogen Preferred regimen
Pneumocystis jiroveci Co-trimoxazole (trimethoprim+
sulphamethoxazole)
Strongyloides stercoralis Ivermectin
Toxoplasma gondii Sulphadiazine and pyrimethamine
Invasive Candida
albicans
Fluconazole
Invasive Aspergillus sp. Voriconazole
Histoplasma capsulatum Amphotericin B liposomal (Ambisome)
then Itraconazole
Cryptococcus
neoformans
Amphotericin B deoxycholate plus 5-flu
Specialist advice is necessary, since dose and duration of therapy depeP. jiroveci (P. carinii)
P.jiroveci is now classified as an atypical fungus. Diag-
nosis is based on the identification of P. jiroveci in broncho-
pulmonary secretions obtained as induced sputum or BAL
fluid. Occasionally transbronchial or open lung biopsy is
necessary. P. jiroveci trophozoites and cysts can be identi-
fied by light microscopy. Increasingly, immunofluorescence
tests are used.
Molecular techniques, including polymerase chain reac-
tion, have a high sensitivity and specificity but are not yet
commercially available.
5.4.3. Treatment of the infectionECCO Statement OI 5F
Specialist advice is appropriate for treating
systemic parasitic or fungal infections [EL5, RG D].Parasitic and fungal infections are uncommon and
individual circumstances such as the level of diagnostic
confidence, degree of immunosuppression, comorbidity and
concomitant therapy make therapeutic decisions complex.
Consequently treatment should be initiated and monitored
and secondary chemoprophylaxis considered if immunomo-
dulator therapy is re-introduced following specialist advice.
General guidance for treatment is shown in Table 6, followed
by more specific information, but specialist advice should be
sought when treating these unusual infections.
P. jiroveci
Prophylaxis regimen: Co-trimoxazole (trimethoprim+
sulphamethoxazole), double strength, 1 tablet three times
a week.
Preferredtreatment regimen:Co-trimoxazole (trimethoprim+
sulphamethoxazole) for about 3 weeks. Cautions: sulphona-
mide may cause marrow suppression or renal impairment
requiring dose adjustment or alternative therapy.
Second line treatment: Intravenous pentamidine for
hospitalised patients, but may cause hyper- or hypotension,ons.
Second-line Duration
Pentamidine 14–21 days
Albendazole 2–3 days
Clindamycin plus
pyrimethamine
21–28 days
Caspofungin At least 14 days
Amphotericin B deoxycholate Until resolution
of symptoms
Amphotericin B deoxycholate 2–3 months
cytosine Fluconazole 6–10 weeks
nd on precise circumstances.
68 J.F. Rahier et al.hyper- or hypoglycaemia, pancreatitis, renal impairment and
numerous drug interactions. Clindamycin with primaquine is
an alternative for outpatients.
S. stercoralis
Prophylaxis regimen: for patients exposed in an endemic
area who are serology positive, take specialist advice.
Preferred treatment regimen: Ivermectin. Cautions: may
exacerbate asthma, or cause rash or fever.
Second line treatment: Albendazole, but may cause
hepatic impairment or marrow suppression.
T. gondii
Preferred treatment regimen: Sulphadiazine and pyrime-
thamine, after a loading dose of pyrimethamine, for about
3 weeks. Give folinic acid. Cautions: sulpha allergy, marrow
suppression.
Second line treatment: Clindamycin with pyrimethamine
and folinic acid.
Invasive candidiasis
Preferred treatment regimen (if C. albicans): Fluconazole
(if no previous use of fluconazole) for at least 2 weeks after
last positive blood culture, or the symptoms and signs have
resolved (if not candidaemic). Cautions: hepatic impair-
ment; clearance reduced in renal impairment.
Preferred treatment regimen (if not C. albicans): Intra-
venous amphotericin B deoxycholate for at least 14 days after
the last positive blood culture, or the symptoms and signs
have resolved (if not candidaemic). Cautions: renal impair-
ment, hypokalaemia, hypersensitivity reactions.
Second line treatment: Caspofungin intravenously for at
least 14 days after last positive blood culture or the symp-
toms and signs have resolved, ambisome, or abelcet.
Invasive aspergillosis
Preferred treatment regimen: Voriconazole until resolu-
tion of symptoms and signs.
Second line treatment: Intravenous amphotericin B deox-
ycholate until resolution of symptoms and signs. Cautions:
Renal impairment; hypokalaemia; hypersensitivity reactions.
Alternatives: Ambisome or abelcet.
H. capsulatum
Preferred treatment regimen: Intravenous amphotericin
B liposomal (Ambisome) for about 3 weeks, followed by
itraconazole for 2–3 months. Cautions: renal impairment,
hypokalaemia, hepatic impairment, drug interactions. Mea-
sure itraconazole concentration.
Second line treatment: Amphotericin B deoxycholate fol-
lowed by itraconazole, or ketoconazole for 3–6 months for
mild disease.
C. neoformans
Preferred treatment regimen: Intravenous amphotericin
B deoxycholate plus 5-flucytosine for 6–10 weeks. Can use
ambisome or abelcet as alternatives to deoxycholate form of
amphotericin. Cautions: renal impairment, hypokalaemia,
infusion reactions, marrow suppression.
Second line treatment: Amphotericin B lisomal (Ambi-
some) plus 5-flucytosine, followed by fluconazole. If no
CNS involvement, fluconazole alone for 3 months may be
sufficient.5.5. Infection occurring during immunomodulator
therapyECCO Statement OI 5G
Starting or continuing immunomodulator therapy
during treatment of parasitic or fungal infection
depends on individual circumstances [EL5, RG
D]. Reintroduction of immunomodulators after
treatment is possible, in conjunction with sec-
ondary chemoprophylaxis. Specialist advice is
appropriate
In the event of parasitic or fungal infection other than oral
or vaginal candidiasis, immunomodulator therapy should be
stopped if possible and standard therapy for the infection
implemented. Common sense dictates that if an opportunis-
tic infection arises as a consequence or in association with
immunosuppression, then it is unwise to reintroduce such
therapy in that patient unless all other options are
considered. None of the case reports, describe reintroduc-
tion of therapy after effective treatment of systemic
parasitic or fungal infection. If a decision is made to re-
introduce immunomodulator once the infection has
responded to treatment, because there are no other options
for controlling the IBD, then consideration should be given to
secondary prophylaxis and specialist advice taken. This takes
into account the treatment options available for the IBD, the
general condition and wishes of the patient.
6. Tuberculosis
6.1. Background
Tuberculosis (TB) and malaria are the most common serious
chronic infectious diseases in the world. The incidence of
tuberculosis is increasing at the start of the third millen-
nium, with the appearance of multiresistant (MDR-TB) and
extremely resistant (XDR-TB) Mycobacterium tuberculosis.
The worldwide incidence of TB in 2005 was 79/100,000
inhabitants. In contrast, the incidence of TB in 1997 was
estimated by the World Health Organisation (WHO) at 10–
24/100,000 inhabitants in most European countries, but
higher (50–99/100,000) in some Southern and Eastern
European countries. Although the incidence, prevalence
and mortality of TB have decreased in Europe, it remains a
global burden. The infection is more prevalent in develop-
ing countries, but migration, together with the HIV pan-
demic (an important reservoir for TB) have increased
concerns of TB in economically-developed areas.251,252 In
the pre-infliximab era, people with IBD appeared to be at
higher risk of TB than the general population. Immunomo-
dulators appear to be the main reason for this increased
risk.253
6.2. Impact of immunomodulator therapy on natural
history of the disease
Anti-TNF therapy further increases the risk of TB infection.
When TB occurs in patients on anti-TNF therapy, it is more
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in 25% of cases), making the diagnosis more difficult.
Mortality in patients with TB during anti-TNF therapy has
been reported to be up to 13%.254–258
6.3. Preventive measuresECCO Statement OI 6A
Patients diagnosed with latent TB should be
treated with a complete therapeutic regimen for
latent TB [EL1b, RG A]ECCO Statement OI 6B
When there is latent TB and active IBD, anti-TNF
therapy should be delayed for at least 3 weeks
after starting chemotherapy, except in cases of
greater clinical urgency after specialist advice
[EL5, RG D]
ECCO Statement OI 6C
Chemotherapy for latent TB may vary according to
geographic areas or patient's epidemiological
background [EL5, RG D]. Specialist advice is
appropriate6.3.1. Impact of preventive actions
Preventive actions (meaning an active search for latent
TB by chest X-ray, tuberculin skin testing, or gamma
interferon assays) have a beneficial impact on the incidence
of overt TB during anti-TNF therapy. Carmona and colleagues
compared the rates of overt TB among patients with rheu-
matic diseases from the Spanish Society of Rheumatology
Database on Biologic Products (BIOBADASER). Patients had a
21-fold higher risk of overt TB compared to the background
Spanish population before preventive actions were pro-
posed. The incidence of TB decreased by 78% after the
adoption of official recommendations (Section 6.4.1). In a
post-marketing surveillance of IFX among 5000 Japanese
patients with rheumatoid arthritis, Takeuchi and co-workers
confirmed that chemoprophylaxis decreased the number of
cases with overt TB.223,259
6.3.2. Chemoprophylaxis
TB chemoprophylaxis regimens principally include
options based on isoniazid (INH) for 6–9 months.259–263
Depending on the geographic area or patient's background,
the possibility of TB infection from multidrug-resistant
strains should be considered. A generally effective regimen
of INH for 6 months does not always prevent infection,
since TB has been reported in two rheumatologic patients
on this regimen.264,265 More aggressive chemoprophylaxis is
appropriate for at risk patients, including those from sub-
Saharan Africa.260,2666.3.3. Concerns about hepatotoxicityECCO Statement OI 6D
In spite of the hepatotoxic potential of some
commonly used drugs in IBD, there are no reports
indicating increased risk for isoniazid hepatotoxi-
city [EL4, RG C], but biochemical monitoring is
considered essentialIsoniazid-related hepatotoxicity occurs in approximately
0.15% of patients. It may occasionally be severe and life-
threatening. The risk of liver damage with isoniazid is
unrelated to the dose or blood concentration, so dose-
modification will not prevent severe liver injury in estab-
lished hepatotoxicity. An increased risk of isoniazid-related
hepatotoxicity in patients with rheumatologic disease on
concomitant methotrexate or sulphasalazine has been
reported, but the association has not been established in
IBD. Minor transaminase elevations (b3-fold) are common
(10–20%) during isoniazid therapy and of no consequence.
Some authors recommend clinical, rather than routine
biochemical monitoring, for patients on isoniazid treatment,
but most advise monitoring liver function at intervals, with
cessation or alteration of therapy if the transaminases exceed
N3-fold elevation associated with hepatitis symptoms or
jaundice, or N5-fold in the absence of symptoms.259,267–271
6.4. Diagnostic approach, screening and treatment
of the underlying infection
6.4.1. Diagnostic approach and screeningECCO Statement OI 6E
Careful evaluation (including history of epidemiolo-
gical risk factors, physical examination, chest X-ray
and tuberculin skin test according to national
guidelines) for latent TB before the use of anti-TNF
therapy is mandatory [EL1b, RG A]. It should also be
considered before corticosteroids or other immuno-
modulators in patients at high risk of TB. Interferon-
gamma release assays (IGRA) are likely to comple-
ment the tuberculin skin test and are preferred in
BCG vaccinated individuals if available [EL4, RG D].
The performance of a second tuberculin skin test
may be considered in immunocompromised patients
1–8 weeks after a first negative tuberculin skin test,
according to national guidelines [EL5, RG D]International guidelines recommend TB risk evaluation
before anti-TNF therapy, based on epidemiological risk
factors, physical examination, chest X-ray, and tuberculin
skin test (TST) for latent TB, but there are local variations. A
diagnosis of latent TB should be considered when there is a
history of recent exposure to the disease and positive initial
tuberculin skin test (TST) or positive booster TST and no
70 J.F. Rahier et al.radiological evidence of active TB. A positiveMantoux reaction
for TST is defined by an induration diameter ≥5 mm. An
abnormal chest radiograph suggestive of old TB (calcification
N5 mm, pleural thickening, or linear opacities) should also be
considered suggestive of latent TB even if other criteria are
absent.260,272–274 These recommendations apply particularly
to anti-TNF therapy. Experience suggests that TB complicating
treatment for IBDwith corticosteroids or immunomodulators is
extremely rare, although the increased risk in populations at
high risk (elderly white males, alcohol abuse, patients from
subcontinental Asia, or Africa) should still be considered.
6.4.2. Tuberculin test distortion by BCG and
immunomodulator therapy
Diagnosis of latent TB by TST may be distorted by prior
BCG (Bacillus Calmette-Guerin) vaccination, because vacci-
nated individuals may become positive reactors to purified
protein derivate (PPD). This distortion is almost insignificant
in adults N30 years of age, irrespective of age at vaccination
or re-vaccination. TST may also be negative in patients on
corticosteroids for N1 month, or thiopurines or methotrex-
ate for N3months. The TSTcannot adequately be interpreted
if corticosteroids are not discontinued for N1 month and
immunomodulators for N3 months. Consequently, a booster
TST may be appropriate for patients on immunomodulators
with a negative TST 1–8 weeks after the first test. A false-
negative TST may also occur during active IBD without
immunosuppression. In clinical practice, booster TST diag-
noses 8–14% additional cases of latent TB among rheumato-
logic or IBD patients.263,271,275–277 Any TST N5 mm should be
considered positive for latent TB.
6.4.3. Interferon γ assays
Two new techniques of interferon γ release assays (IGRA)
that target two specific proteins of M. tuberculosis (ESAT-6
and CFP-10). These are not affected by BCG-vaccination or
environmental mycobacterial exposure and are commer-
cially available (ELISPOT and QuantiFERON®-TB). Multiple
studies, especially in immunocompetent patients, have
demonstrated that IGRA is more sensitive and specific than
a standard TST. In immunocompromised patients, IGRA seems
to be more sensitive and specific than a standard TST.
Further studies are urgently needed.278–288
6.5. Infection occurring during immunomodulator
therapy
6.5.1. Management of immunomodulator therapyECCO Statement OI 6F
TB must be excluded in the event of persistent
fever or non-specific clinical deterioration during
immunomodulator therapy. If TB is diagnosed, anti
TB-therapy must be started, anti-TNF therapy
must be stopped and can be resumed after two
months if needed [EL4, RG D]. It appears that 5-
ASA, azathioprine, methotrexate or steroids do
not need to be discontinued, provided that multi
drug resistant TB has been excluded [EL4, RG D]In case of active TB, TB treatment should ideally be
completed before starting biological therapy.
In the initial report of TB incidence during anti-TNF
therapy, 57% of cases were extra pulmonary and mortality
was 13%. TB should be excluded as a cause of deterioration
during anti-TNF therapy even if the clinical features are not
suggestive of TB.256,263
No prospective or controlled data are available on the
ideal timing of anti-TNF therapy once TB treatment has
begun. It has been proposed that TB therapy should be
supervised by a thoracic physician or infectious disease
specialist. It has also been suggested that anti-TNF treat-
ment is either best delayed until completion of an anti-
tuberculosis treatment, or that it should be avoided until at
least 2 months after TB treatment has begun.289,290
Although there are no data assessing the impact of
thiopurine therapy on the risk of TB in patients also receiving
anti-TNF therapy, results from a small case–control study in
rheumatoid arthritis have shown that the incidence of TB
among patients using corticosteroids and immunomodulators
is not increased.264 This suggests that these medications can
be continued during treatment of TB, although larger studies
are warranted.
7. Bacterial infection
7.1. Streptococcus pneumoniaeECCO Statement OI 7A
Patients with inflammatory bowel disease on
immunomodulators are considered to be at risk
patients for pneumococcal infections [EL4, RG C]ECCO Statement OI 7B
Preventive strategy consists of a pneumococcal
vaccination and with a single revaccination 3–
5 years if the patient is still immunocompromised
[EL5, RG D]. Immunity to S. pneumoniae after
polysaccharide vaccination is not affected by
corticosteroids or anti-TNF therapy [EL2a, RG B],
nor by azathioprine [EL2b, RG C]. Methotrexate
treatment is associated with much lower pneumo-
coccal vaccine-induced seroconversion [EL2a, RGB]ECCO Statement OI 7C
Immunomodulator therapy should be temporarily
withheld until the resolution of active infection [EL5,
RGD]. Treatment of pneumonia in patients on immu-
nomodulators must always cover S. pneumoniae7.1.1. Background
S. pneumoniae is a Gram-positive facultative anaerobic
coccus which may cause serious or lethal infections including
71Consensus on the prevention, diagnosis and management of infections in inflammatory bowel diseasepneumonia, sepsis, or meningitis.291 IBD patients on immu-
nomodulators are considered high-risk patients for invasive
pneumococcal disease.117,214 In cohort studies bacterial
pneumonia is one of the most prevalent infections in IBD
patients on immunomodulators.26,292 Invasive infection
with S. pneumoniae related to immunomodulators in
IBD has been reported.293 Current recommendations for
the 23-valent pneumococcal vaccine include patients on
immunomodulators.216
7.1.2. Impact of immunomodulator therapy on the natural
history of the disease
Host defences against Streptococcus spp. depend on both
humoral and cellular immunity. Predisposing conditions to
pneumococcal infection are numerous, including immuno-
suppression in about a third of all diagnosed cases.294 We did
not find studies relating specific drugs to risk, although cases
have been described with several drugs, including anti-TNF
therapy. Although the incidence seems to be increased in
immunocompromised patients, we did not find studies
documenting the degree of increased severity or worse
outcomes in these patients.
7.1.3. Preventive measures
The 23-valent pneumococcal vaccine should ideally be
administered before the start of immunomodulator therapy,
since immunomodulators may reduce the antibody response
to the vaccine. This has been shown in patients with
rheumatic diseases.291,295–299 Therefore, the vaccine is
best administered at the time of IBD diagnosis, or at least
two weeks before the start of immunomodulators.291 Repeat
vaccination is recommended after three to five years if the
patient remains on immunomodulator therapy117,291 (http://
www.cdc.gov/mmwr/PDF/rr/rr4608.pdf).
7.1.4. Diagnostic approach, screening and treatment of
the underlying infection
Diagnostic approach and screening
The most frequent and severe manifestations of pneumo-
coccal infection are pneumococcal pneumonia and pneu-
mococcal meningitis (with or without pneumococcal
bacteremia). For both conditions it is not possible to
differentiate a pneumococcal aetiology from other bacter-
ial causes on the basis of the history or clinical signs.
Whenever possible, relevant clinical samples (blood,
cerebrospinal fluid, good respiratory sample) should be
taken, analysed and cultured upon presentation, but this
should not delay treatment.
Treatment of the infection
Empirical treatment should be started immediately for
eithermeningitis or pneumonia covering S. pneumoniae and
other common bacterial causes. The choice of antibiotic
should follow local guidelines based on local epidemiology,
because penicillin susceptibility varies widely.300,301
7.1.5. Infectionoccurringduring immunomodulator therapy
Management of immunomodulator therapy
Antibiotic treatment of pneumonia in patients with IBD
should always cover S. pneumoniae. Penicillin is the stan-
dard antibiotic for penicillin-susceptible pneumonia and
meningitis, but local advice on resistance is appropri-
ate,302 especially since their immunosuppression may beassociated with an increased risk of penicillin resistance.
In the event of invasive pneumococcal infection, immu-
nomodulator therapy is best temporarily withheld until
resolution of the infection.26,293,303
7.2. Legionella pneumophilaECCO Statement OI 7D
Patients with inflammatory bowel disease on
immunomodulator therapy with pneumonia
should be tested for L. pneumophila [EL4, RG D]ECCO Statement OI 7E
Immunomodulator therapy should temporarily be
withheld until resolution of the active infection
[EL5, RG D]7.2.1. Background
L. pneumophila is an aerobic Gram-negative coccobacil-
lus causing pneumonia, which can be fatal.304 The most
common route of transmission is airborne and reservoirs
include aquatic systems such as cooling towers, evaporative
condensers, humidifiers and decorative fountains.305
7.2.2. Impact of immunomodulator therapy on natural
history of the disease
Immunomodulator therapy is consideredahigh-risk condition
for infection with L. pneumophila.304 Invasive L. pneumophila
infections, some with fatal outcome, related to immuno-
modulators for IBD or rheumatological patients have been
reported.306–311
7.2.3. Preventive measures
Novaccine isavailableandeffectivechemoprophylaxis hasnot
been described. Since most epidemics of L. pneumophila can be
linked to water reservoirs, prophylactic measures include regular
cleaning and maintenance of different water systems.305
7.2.4. Diagnostic approach, screening and treatment of
the underlying infection
Diagnostic approach and screening
Clinically and radiologically Legionella pneumonia cannot
be distinguished from pneumococcal pneumonia. The key to
diagnosis is appropriate microbiological culture, in associa-
tion with real-time PCR if available. Serological testing and
antigen detection in the urine are also available.304
Treatment of the infection
Treatment for L. pneumophila consists of macrolide or
fluoroquinolone antibiotics. Empirical treatment of severe
community-acquired pneumonia should always cover L.
pneumophila especially in the immunocompromised.300,301
7.2.5. Infectionoccurring during immunomodulator therapy
Management of immunomodulator therapy
Curative treatment consists ofmacrolideor fluoroquinolone
antibiotics.304,309 Immunomodulator therapy is best tem-
porarily withheld until resolution of the active infection,
72 J.F. Rahier et al.although recurrent infection has been reported, so careful
consideration is necessary about the benefit of continuing
immunomodulators.309
7.3. Salmonella speciesECCO Statement OI 7F
Patients receiving immunomodulators are at risk
of more severe infections with Salmonella enter-
itidis and S. typhimurium [EL4, RG C]ECCO Statement OI 7G
Prevention of Salmonella sp. infections consists of
foodhygiene (avoiding raweggs, unpasteurizedmilk
and insufficiently cooked or raw meat) [EL5, RG D]
ECCO Statement OI 7H
Immunomodulators should be temporarily with-
held until resolution of the active infection [EL5,
RG D]7.3.1. Background
Salmonella is an aerobic Gram-negative bacillus caus-
ing enterocolitis or systemic infection. S. enteritidis and
S. typhimurium are the most common serotypes.312,313
Infection is typically acquired through consumption of
contaminated food or water. Early infection starts within
the gastrointestinal tract, but patients may present with
symptoms of disseminated infection such as sepsis, menin-
gitis, urinary tract infection, or reactive arthritis.312
7.3.2. Impact of immunomodulator therapy on natural
history of the disease
Immunomodulator therapy is considered a high-risk predis-
posing condition for intestinal or systemic infections with Sal-
monella spp.314 Invasive Salmonella spp infection, some with
fatal outcome related to immunomodulator therapy for IBD or
rheumatologic patients have been reported.221,306,310,315–319
7.3.3. Preventive measures
Prevention consists of food hygiene: advise immunocom-
promised patients to avoid the consumption of raw eggs
(fresh mayonnaise), unpasteurised milk and undercooked or
raw meat (including carpaccio).312
7.3.4. Diagnostic approach, screening and treatment of
the underlying infection
Diagnostic approach and screening
The diagnosis should always be considered in patients with
fever.Definitivediagnosis of enteric fever ismadeby isolating
S. typhi or other Salmonella sp. from blood, stool, or urine.
Treatment of the infection
Salmonellosis is treated with antibiotics such as fluor-
oquinolones or third-generation cephalosporins, depend-
ing on the local susceptibility pattern.7.3.5. Infection occurring during immunomodulator
therapy
Management of immunomodulator therapy
Empirical treatment for severe infections without a clear
focus or suspicion of enteric fever should always cover
Salmonella sp., using fluoroquinolones or cephalosporins.
Curative treatment of confirmed Salmonellosis consists of
fluoroquinolones or third-generation cephalosporins,
depending on local susceptibility patterns.302 Immunomo-
dulator therapy is best temporarily withheld until resolu-
tion of the active infection, although recurrent infection
and asymptomatic carriage can occur. Confirmation of
clearance through stool culture in immunocompromised
patients seems advisable.
7.4. Listeria monocytogenesECCO Statement OI 7I
Patients receiving immunomodulators are at risk
of systemic and central neurological infections
with L. monocytogenes [EL4, RGC]. The incidence
appears higher in patients treated with anti-TNF
therapy compared to other immunomodulatorsECCO Statement OI 7J
Prevention includes avoidance of unpasteurized
milk or cheese, uncookedmeat and raw vegetables,
especially during pregnancy [EL5, RG D]. Patients
on anti-TNF therapy who present withmeningitis or
other neurological symptoms demand full attention
and should be thoroughly investigated as soon as
such symptoms develop [EL5, RG D]ECCO Statement OI 7K
Anti-TNF therapy should be discontinued during
infection. No Consensus was reached on whether
anti-TNF therapy should not be re started
7.4.1. Background
L. monocytogenes is an aerobic Gram-positive and faculta-
tive intracellular bacillus.320 It is an opportunistic food-borne
pathogen which has the capacity to survive many food-
processing procedures. L. monocytogenes can cause relatively
mild gastroenteritis, but in IBD or rheumatologic patients on
immunomodulator therapy, it may lead to systemic sepsis,
meningoencephalitis, or rarely cholecystitis and arthri-
tis.221,306,310,317,321–326 The mortality rate of systemic infection
is ashighas30%,evenwithantibiotic therapy.327 Infectionduring
pregnancy often leads to spontaneous abortion or stillbirth.327
7.4.2. Impact of immunomodulator therapy on natural
history of the disease
Immunomodulator therapy is considered a high-risk pre-
disposing condition for infections with L. monocytogenes.327
73Consensus on the prevention, diagnosis and management of infections in inflammatory bowel diseaseCompared to other immunomodulator therapies, anti-TNFα
treatment appears to carry a particular risk for serious
infection with L. monocytogenes.310,326
7.4.3. Preventive measures
Prevention consists of food hygiene: avoid soft or un-
pasteurised cheese, unpasteurised milk, undercooked meat
and raw vegetables.326,327
7.4.4. Diagnostic approach, screening and treatment of
the underlying infection
Diagnosis is made by appropriate microbiological culture
and curative treatment consists of ampicillin, amoxicillin, or
sulphamethoxazole/trimethoprim.302
7.4.5. Infection occurring during immunomodulator
therapy
Management of immunomodulator therapy
Early infection starts within the gastrointestinal tract. A
high index of suspicion in patients on immunomodulator
therapy who present with signs of meningitis or other neu-
rological symptoms is appropriate, with intensive investi-
gation including lumbar puncture as soon as such symptoms
develop.326 When patients have meningoencephalitis with-
out initial proof of Listeriosis, the pathogen should still be
covered by the antibiotic regimen. No data are available on
whether immunomodulators should be temporarily or
indefinitely withheld in the event of active infection.
7.5. Nocardia speciesECCO Statement OI 7L
Patients receiving anti-TNF therapy have been
reported to be at risk of systemic and cutaneous
infections with Nocardia spp., particularly when
they are also treated with corticosteroids [EL4,
RG C]ECCO Statement OI 7M
The prevention of Nocardia sp. infections consists
of avoiding direct contact with soil or inhalation of
soil contaminated dust [EL5, RG D]ECCO Statement OI 7N
Anti-TNF therapy should be discontinued indefi-
nitely in the event of infection with Nocardia sp.
[EL5, RG D]
7.5.1. Background
Nocardia species are aerobic Gram-positive, weakly acid-
fast actinomycetes. They are ubiquitous soil organisms,
responsible for local skin infections through direct contact, or
necrotising pulmonary infections through inhalation.328 Hae-
matogenous dissemination to the brain occurs in up to 33% of all
cases, most of which occur in immunocompromised hosts.3287.5.2. Impact of immunomodulator therapy on natural
history of the disease
Nocardia species infection is increasingly found in the
immunocompromised patient. People with IBD or rheumato-
logic disease on immunomodulator therapy are considered at
risk. Reports of cutaneous, pulmonary, or neurologic Nocar-
dia sp. infection in patients on anti-TNFα treatment or
corticosteroids have been published.221,310,329–331
7.5.3. Preventive measures
The prevention of cutaneous Nocardia sp. infections
consists of skin hygiene, avoiding soil-infected skin lesions
and avoiding inhalation of soil-contaminated dust.328
7.5.4. Diagnostic approach, screening and treatment of
the underlying infection
Diagnostic approach and screening
Nocardia sp. can be diagnosed rapidly by examination of
sputum, pleural, or bronchial lavage fluid by Gram stain
and a modified acid-fast stain. Long-term culture up to six
weeks is necessary to grow the pathogen.328
7.5.5. Infection occurring during immunomodulator
therapy
Management of immunomodulator therapy
Treatment consists of sulphamethoxazole/trimethoprim
and/or ceftriaxone. Antibiotics should be continued until
the disappearance of all lesions, which can take several
months.328 All immunocompromised patients (regardless
of the site of disease) and patients with neurological
involvement are best treated for at least one year and
some suggest indefinitely, especially if patients continue
to be immunosuppressed as a result of their disease or
treatment.294 In order to obtain complete resolution of
the infection, case reports suggest that anti-TNFα
treatment should be discontinued indefinitely.329,330
7.6. Clostridium difficile
7.6.1. BackgroundECCO Statement OI 7O
The pattern, virulence and presentation of C.
difficile are currently changing. Inflammatory
bowel disease is an independent risk factor for
infection with C. difficile. In inflammatory bowel
disease C. difficile is mostly community-acquired.
Patients with colitis are particularly susceptible.
Concomitant diagnosis of inflammatory bowel
disease and C. difficile-associated diarrhoea
(CDAD) is a predictor of an increased need for
hospitalisation and increased mortality [EL2, RG B]The pathogenicity of C. difficile is dependent on toxin
production. Two main toxins are secreted by the vegetative
forms of the germ, toxins A (enterotoxin) and B (cytotoxin).
C. difficile-associated disease (CDAD) typically presents with
74 J.F. Rahier et al.watery diarrhoea (at least five bowel movements of liquid or
unformed stool during 36 h), malaise, abdominal pain, fever,
or leukocytosis.332,333
A retrospective observational study at a US referral
centre in 2007, reported a significant rise of C. difficile
infections in IBD patients, from 1.8% in 2004 to 4.6% in
2005.334 The adjusted odds ratio for the development of
CDAD was 2.9 (95% CI 2.1–4.1) in IBD patients compared to
non-IBD. The adjusted OR was 2.1 for CD (95% CI 1.3–3.4),
4.0 for UC (95% CI 2.4–6.6) and the diagnosis of IBD was an
independent risk factor for CDAD.335 A significant rise in
hospitalisation for IBD complicated by C. difficile infec-
tions between 1998 and 2004 has been reported (24/1000 vs
39/1000 for UC, 8/1000 vs 12/1000 for CD), including
prolongation of hospital stay and a four-fold increase in
mortality.336 Colectomy is necessary in a substantial number
of patients.
7.6.2. Impact of immunomodulator therapy on the natural
history of the disease
Immunomodulators are a known risk factor for acquisition
of C. difficile and development of CDAD. Experience from
solid organ transplantation shows an increase in incidence
and severity of CDAD after transplantation.337 Immunosup-
pression may also be an independent risk factor for mortality
in patients with CDAD.338 Data regarding IBD patients,
immunosuppression and CDAD remain sparse. In one study
maintenance immunomodulators, but not biologic therapy,
were independently associated with the emergence of CDAD
in IBD.334
7.6.3. Preventive measuresECCO Statement OI 7P
Chemoprophylaxis for CDAD is not warranted.
Hygiene procedures in a nosocomial setting are
recommended [EL2, RGB]. The safety and efficacy
of probiotics remain to be established
Alcoholic hand rubs do not eliminate C. difficile spores.
Furthermore, the presence of disinfectants can provoke
sporulation. Mechanical elimination of spores by soap and
handwashing is recommended.339 Hypochlorite solutions
(unbuffered or phosphate-buffered) have been shown to
reduce C difficile contamination even in high touch areas
(bed rails, switches, bed-side telephones, or call buttons).340
Even though data from controlled trials are lacking, studies
suggest a decrease in CDAD cases when bleach is used as a
cleaning agent.341,342 Patients diagnosed with, or strongly
suspected with infection, should be placed in isolation (single
rooms) or cohorted together. Care workers should wear
disposable gowns and gloves when entering the patient's
room.
Recurrent CDAD has been treated effectively by Sacchar-
omyces boulardii, confirmed by meta-analysis.343 On the
other hand, methods and source data for this metaanalysis
are disputable, so they do not provide sufficient evidence to
recommend probiotics or prove their safety in the treatment
of CDAD. Occasional cases of fungaemia in immunocompro-
mised patients taking S. boulardii have been reported.7.6.4. Diagnostic approach, screening and treatment of
the underlying infection
Diagnostic approach and screening
ECCO Statement OI 7Q
Screening for C. difficile is recommended at every
flare in patients with colonic disease [EL3, RGD].
Tests for both cytotoxins A and B are recom-
mended [EL2, RG B]In routine clinical practice, several different laboratory
tests can be used to diagnose C. difficile infection: toxin
detection (93% laboratories in Europe, of which 79% use
enzyme immunoassay for toxin A and/or toxin B and 17%use
the tissue cytotoxicity assay for toxin B), culture of C.
difficile (55% laboratories), glutamate dehydrogenase
detection (6% laboratories) and PCR (2% laboratories).344
Enzyme immunoassays (EIA): detect the toxins (A and/or B)
produced by toxigenic strains of C. difficile. There are
numerous commercially available EIAs with different
sensitivities and specificities (ranging from 63–99% and
75–100% respectively). Since development of CDAD does
not depend on the presence of both toxins, while toxin A-
negative C. difficile strains account for up to 3% of CDAD,
EIAs designed to detect only toxin A are likely to under-
report CDAD. Toxin A-specific EIAs were applied in 58%
laboratories, surveyed in 2003.345,346 although more now
use EIAs designed to detect both toxin A and toxin B. Cul-
ture of C difficile: performed on selective agar (e.g.
cycloserine, cefoxitim agar). Before innoculation with
stool, an enrichment step can be performed by exposure
to alcohol to select spore-forming bacteria. Incubation
time is usually 48 h. C. difficile can then be identified by
morphological criteria, characteristic odour and antigen-
detection by latex agglutination. Cytotoxicity assay: for C
difficile toxin B (TcdB). This still represents the diagnostic
gold standard despite its long turnaround time (24–
48 h).347,348 It uses the cytopathic effect of toxin B on the
cytoskeletal structure of mammalian cell culture lines,
which can be abrogated by C. difficile or C. sordelli
antitoxin. PCR: detection by amplifying the tcdB gene.
Sensitivity and specificity for PCR were 87.1% and 96.5%
respectively, compared to the cytotoxicity assay. Positive
and negative predictive values were 60.0 and 99.2%
respectively.349 Real time PCR had a higherculture than
EIAs. Detection in IBD: Between 5.5% and 19% stool samples
are reported to be positive for C. difficile among IBD
patients with a relapse.350,351 Consequently, stool testing
forC. difficile seems to have a high yield during flares of IBD
and is generally considered appropriate. The endoscopic
picture of C. difficile-associated disease usually shows
diffuse or scattered erythema. Pseudomembranes are only
rarely found and their absence does not exclude infection.
For CDAD in IBD, no patient who was positive for C. difficile
showed the pathognomonic pseudomembranes in endo-
scopy. In the general population, endoscopy has only
limited sensitivity (50%) and cannot be recommended as a
diagnostic tool for CDAD.352
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Metronidazole and oral vancomycin are equally
effective in treating mild to moderate CDAD [EL1,
RG B]. It remains to be established if this applies to
patients with inflammatory bowel disease. Other
antibiotics should be stopped if possible. For severe
CDAD, vancomycin has been shown to be superior in
patients without inflammatory bowel disease [EL1,
RGB] and is thereforepreferable. In case ofmultiple
recurrences, pulsed dosing of vancomycin is a rea-
sonable treatment option and withdrawal of immu-
nomodulators should be considered [EL2, RG B]In a meta-analysis, antimicrobial exposure has been shown
to be an independent risk factor for both C. difficile
carriage (pooled OR=4.2, 95% CI=3.1–5.9) and CDAD
(pooled OR=5.9, 95% CI=4.0–8.5) in the general popula-
tion.353 Almost all classes of antibiotics and broad spectrum
antibiotics in particular are associated with CDAD, with the
exception of aminoglycosides. Recent studies have empha-
sized the importance of fluoroquinolones, which seem to
pose the greatest risk for the development of CDAD com-
pared to other common antimicrobials.354,355 The first step
in the treatment of CDAD is withdrawal of antibiotics, a
measure which leads to recovery in up to 25% of non-IBD
patients with CDAD.356,357 Data from IBD are lacking.
Metronidazole is generally first line therapy for patients
experiencing a first, or even a second episode of CDAD358
although this depends on local susceptibility. The usual oral
treatment regime is 200–250 mg four times daily or 400–
500mg three times daily for 10 to 14 days. The glycopeptide
antibiotic vancomycin is highly effective for CDAD and
preferable for multiple recurrences of CDAD, or if there is
local resistance to metronidazole.359 Vancomycin is not
superior to metronidazole for the first or second episode of
CDAD, but is more costly and runs the risk of promoting
resistance among enterococci.357,360 Nevertheless, for
patients with symptoms of severe CDAD, or if the patient's
condition fails to improve or deteriorates on metronida-
zole, then early use of vancomycin is recommended.361
Signs of severe CDAD include a systemic inflammatory
response (tachycardia, fever), electrolyte imbalance,
volume depletion, hypotension, ileus, toxic megacolon or
peritonitis. The dose of vancomycin for acute CDAD is
125 mg every 6 h, which is of equivalent efficacy to 500 mg
four times daily.362 To reduce the recurrence rate of CDAD,
a tapered or pulsed treatment regimen with vancomycin
has been proposed on the basis of significantly reduced
relapse rates following pulsed schedules. A pulsed schedule
means vancomycin 125–500 mg every three days for 2–
3 weeks.359 It is unexpected, but notable that reported
recurrence rates in IBD patients with CDAD are low com-
pared to the general population (0.1% vs 8.7%) which
questions the necessity of a pulsed treatment approach.335
More data are needed and much higher recurrence rates of
CDAD have been reported.7.6.5. Infection occurring during immunomodulator
therapyECCO Statement OI 7S
In CDAD it remains to be established whether
concomitant therapy with immunomodulators
should be withheld [EL5, RG D]
There are insufficient data to recommend a strategy for
managing CDAD in patients on immunomodulators. Azathiopr-
ine/6-mercaptopurine therapy, but not biological (anti-TNFα)
therapy has been significantly associated with C difficile
infection.334 Up to 78% of IBD patients positive for C difficile
in this study were reported to be taking immunomodulators or
anti-TNFα therapy, but the study was not sufficiently powered
to address attributable risk. Clearly the risk and benefit of
immunomodulator therapy should be questioned in such
patients, but it remains a matter of clinical judgement as to
whether immunomodulators should be withdrawn. Steroids
have been reported to be of therapeutic value in severe CDAD in
a single small case-series363 so there seems no reason to avoid
corticosteroids.
8. Special situations
8.1. Patients travelling frequently or to less
economically developed countries
8.1.1. Guidelines for the IBD patient travelling to less
economically developed countries
The traveller with IBD is exposed to two main risks during
travel:
(i) relapse, exacerbation, or complications of the under-
lying IBD due to gastrointestinal infections acquired
during travel, change in dietary habits, decreased
compliance with IBD medication, or lack of such
medication due to bad planning or unexpected change
in the travel itinerary
(ii) Acquiring infectious diseases endemic to developing
countries which may be more severe in IBD patients
who are immunosuppressed.
These patients are therefore best advised to consult their
gastroenterologist as well as a professional travel advisory
clinic prior to travel. The clinician should ensure that the
traveller understands the risks involved from their proposed
itinerary. The medical requirements of the patient and
degree of immunocompromise should also be taken into
consideration when planning the journey, to minimise
medical risks during travel.
8.1.2. Pre-travel consultation
Pre-travel interventions should be evaluated for both safety
and efficacy. For example, patients with IBD taking IMs should be
discouraged from visiting South American or sub-Saharan African
countries where yellow fever is endemic, or yellow fever vaccine
(a live attenuated vaccine) is required. Furthermore, patients
with IBD should ideally be provided with adequate medication,
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exacerbationof theirunderlyingdisease inaremote locationwhere
medical assistance may not be readily available, and adequate
health insurance which includes cover for evacuation by air.
Guidelines regarding which vaccinations to take and when,
or what preventive measures or drugs to use when travelling to
less economically developed countries are frequently updated
by the Infectious Diseases Society of America.364 Vaccine-
preventable diseases include: hepatitis A, typhoid fever, yellow
fever, Japanese B encephalitis, meningococcal meningitis, tick
born encephalitis, poliomyelitis, influenza, mumps, measles,
diphtheria, and tetanus. Malaria, traveller's diarrhoea, tuber-
culosis and insect-borne diseases are also considered.
This section addresses three principal questions:
1. Do these diseases behave differently when affecting IBD
patients?
2. Do these diseases behave differently in IBD patients
treated with IM/biologicals?
3. What is the degree of immunosuppression and what is its
influence on the success of preventive measures and on
their safety.
8.1.3. Do these diseases behave differently in IBD patients?ECCO Statement OI 8A
The clinical manifestations, complications and
response to therapy of travel-associated diseases
among travellers with inflammatory bowel disease
are unknown. Infections with enteropathogenic
microorganisms may cause reactivation of quies-
cent inflammatory bowel disease [EL4, RG C].
Patients with inflammatory bowel disease should
have a pre-travel consultation. Travellers with
inflammatory bowel disease should be aware of
the balance of risks between immunomodulator
therapy and travel related infections
The effect of travel-associated diseases on the clinical
manifestations of IBD has never been studied. However, several
epidemiological investigations indicate that infections with
enteropathogens which might be acquired during travel, can
both provoke the initial onset of IBD and are associated with
reactivation of quiescent disease.365 Powell and Wilmont
showed in the 1960s that following epidemics of Salmonella,
Shigella, or Yersinia sp., a small but reproducible percentage
of patients develop typical IBD.366 The onset of IBD has also been
described following sporadic infectionwith enteropathogens.367
8.1.4. Do travel-associated diseases behave differently in
patients on immunomodulators?ECCO Statement OI 8B
The effect of immunomodulators on the onset and
severity of preventable, travel-associated dis-
eases in patients with inflammatory bowel disease
is not fully known [EL5, RG D]An extensive literature search yielded only scant case
reports regarding the contraction of travel-associated or
vaccine-preventable infections by immunocompromised
patients. For example, steroid use was associated with fatal
paralytic poliomyelitis in one patient following administration
of live oral polio vaccination to his daughter. Six patients in
south-east Asia developed malaria, one fatal, one asympto-
matic, while taking steroids and other immunosuppressants.
Malaria has also been reported in a patient receiving
azathioprine and other immunosuppressive drugs after kidney
transplantation. It is interesting that ciclosporin may have a
protective influence, including an anti-parasitic effect in
malaria and a possible decrease in HBV replication. Anti-TNF
drugs have been associated with reactivation of HBV in some
patients and malaria (in one patient).
In most cases, the diseases did not behave differently and
the drugs were not given as mono-therapy. Moreover, the
disease for which the drug was administered was not IBD in
most cases. Thus it is impossible to extrapolate the real
effect of a single drug on the severity of these preventable
diseases in patients with IBD.
8.1.5. The influence of immunosuppression on the safety
and efficacy of preventive measures
Immunisation of patients with IBD against travel-asso-
ciated vaccine-preventable diseases is highly desirable,
given their altered immune status which predisposes them
to infectious diseases and possible severe course of disease,
once contracted.
Three main issues have to be addressed when considering
vaccination of patients with IBD on immunomodulators:
1. The safety of the vaccine
2. The possibility of exacerbating IBD due to vaccination
3. The efficacy of vaccination and modes of monitoring
acquisition of immunity.
Vaccination safety
Effect of vaccination on IBD: Many alterations in immune
function have been described in patients with IBD and it is
generally considered that an over-active adaptive immune
system is driving the chronic inflammatory state in these
patients. There are no reports of an increased rate of adverse
outcomes following immunisation in patients with IBD not
being treated with IMs. Furthermore, no vaccine has been
shown to be associated with the initiation or exacerbation of
IBD, despite speculation regarding the measles vaccine.368ECCO Statement OI 8C
Immunisation before travel for patients with
inflammatory bowel disease who are not on
immunomodulators should follow standard guide-
lines for healthy travelers, according to travel
destination [EL5, RG D]
Inactivated vaccines: There are few systematic data re-
garding the safety of vaccines in patients with IBD being treated
with immunomodulators, so inference from immunosuppressed
patients with other disorders is necessary. Killed, inactivated or
recombinant vaccines have beenadministered tomanypatients
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as other disorders (transplantation, rheumatic disorders, and
chronic pulmonary disease). Most studies have examined
responses to DTP, Influenza, Pneumococcus or Hepatitis B
vaccines. There are no reports of infectious complications
caused by killed or inactivated vaccines and adverse events
have been found to be similar to healthy controls. Therefore,
clinical guidelines consistently advocate vaccination of immu-
nosuppressed patients for appropriate indications.369–372ECCO Statement OI 8D
Vaccination is best given before immunomodula-
tor therapy [EL 4, RG D]
ECCO Statement OI 8E
Non-live vaccines are generally considered safe in
patients with inflammatory bowel disease regard-
less of immunomodulator therapy, but may be less
effective. This includes — Diphtheria and tetanus
toxoids, acellular pertussis, inactivated parent-
eral poliovirus vaccine, Influenza, Pneumococcal
polysaccharide, recombinant Hepatitis B vaccines
[EL2a, RGB], as well as Hepatitis A, parenteral
Typhoid (Salmonella typhi Vi polysaccharide),
Meningococcal polysaccharide, oral killed Cho-
lera, inactivated Japanese encephalitis, Human
papilloma virus and inactivated tick-borne ence-
phalitis vaccines [EL4, RG C]
Live-attenuated vaccines, including family exposure:
These are generally considered unsafe for immunosuppressed
patients, due to concerns about the possibility of causing
disease by the otherwise attenuated organism. For instance,
a patient on long standing prednisolone treatment (12.5 mg/
day) was reported to succumb to fatal paralytic poliomyelitis
2 months after his daughter received live oral polio
vaccine.373 However, live-poliomyelitis vaccine-associated
disease has also been reported in persons with an intact
immune system, so the implications of this case are difficult
to interpret. Nevertheless, the CDC guide on contraindica-
tions to vaccination advise against administering live-
attenuated vaccines to patients treated by long-term
immunosuppressive therapy, including steroids. Such vac-
cines includeMeasles–Mumps–Rubella (MMR), Typhoid Ty21a,
Vaccinia, Yellow fever, live-attenuated influenza vaccine
(LAIV) and BCG, which are designated as contraindicated in
such patients.372 On the other hand, in a single retrospective
observational study, 49 children with Juvenile Rheumatoid
Arthritis received the MMR vaccine while being treated with
methotrexate (MTX, mean dose 11 mg/m2), some also being
treated with prednisolone. None of the patients developed
measles following the vaccination.374 Moreover, MMR was
administered safely to 31 pediatric patients after liver
transplants under tacrolimus or ciclosporin.375 The CDC
does not take a position on the safety to the parent receiving
immunomodulators whose child is vaccinated. This is not that
uncommon in patients with IBD, when themother or father ofa baby due to have MMR may be receiving steroids,
azathioprine or other IMs. However, no case of measles has
been reported in such circumstances.
Varicella live virus vaccine is probably safe in patients who
have stopped thiopurines or MTX for at least one week before
and one week after vaccination although longer than a
week's cessation of thiopurines or MTX may be desirable.
However, the available data is derived from the pediatric
population. In studies recently reviewed by the Canadian
national advisory committee on vaccination over 1000
pediatric patients with acute lymphoblastic leukaemia
(ALL) in remission received varricella vaccine. Many of
these children were under maintenance therapy, which was
withheld for 1 week before to 1 week after vaccination. Mild
vaccine-related rash was seen in 40–50% of patients, and
fever in 20%. Of patients who developed rash, 40% were
treated by acyclovir, and no severe life-threatening adverse
events were reported. Thus, varicella vaccine to ALL
children was incorporated into clinical guidelines advocating
withholding chemotherapy at least 1 week before to 1 week
after vaccine.376 However, there is no data to support the
safety of this approach in immunosuppressed IBD patients.
Despite the lack of evidence, some expert opinion groups
contend that live-virus vaccines can be given safely to
children receiving prolonged prednisolone treatment at a
dose (b2 mg/kg/day or b20 mg prednisone/day if weighing
more than 10 kg), and also to children receiving higher doses
for less than 14 days.117,372
ECCO Statement OI 8F
Live attenuated vaccines are contra-indicated in
IBD patients on immunomodulator therapy (MMR,
Typhoid Ty21a, Vaccinia, Yellow fever, live atte-
nuated influenza vaccine, varicella, oral polio and
BCG) [EL5, RG D]. Live-virus vaccines are probably
safe in patients on less than 20 mg prednisone
daily, or on higher doses provided they have been
given for less than 14 days [EL5, RG D]ECCO Statement OI 8G
It is generally recommended that administration
of live attenuated vaccines should be avoided for
at least 3 months after treatment with immuno-
modulators is stopped. This delay may be reduced
to 1 month in case of use of corticosteroids alone.
Immunomodulator therapy should also be with-
held for at least 3 weeks from the time of a live
vaccine injection [EL5, RGD]
Acquisition of adequate immunity [Vaccine response in
patients on immunomodulators or biological therapy]
CD and UC patients have been reported to have a reduced
humoral response to booster Tetanus immunisation, inde-
pendent of steroid therapy.377 The ability of immunosup-
pressed patients to acquire immunity to infectious agents
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and the specific immunosuppression regimen.
Influenza vaccine: Thus, in three controlled studies,
patients with rheumatoid arthritis on anti-TNF therapy
generated similar rates of protective antibodies to influenza
vaccine, albeit at a lowermean titre, compared to patients not
taking these drugs, or normal controls.211–213 Similarly, patients
with rheumatoid arthritis treated with MTX did not have
reduced immunity after influenza vaccine immunisation.211,213
In two controlled studies of lupus patients, azathioprine, but
not prednisolone (10 mg), reduced seroconversion to influenza
vaccine.378,379 In another study of 59 renal transplant recipi-
ents, patients treated with azathioprine and prednisolone had
similar seroconversion rates to influenza vaccine as healthy
controls, but patients on ciclosporin andprednisolone exhibited
reduced immunity.380 Prednisolone at doses N10 mg/day did
not affect the immune response to influenza vaccine, either in
patients with chronic pulmonary disease in a prospective
controlled trial381 or rheumatoid arthritis.211
Pneumococcal vaccine: In two controlled studies, patients
with rheumatoid arthritis on various anti-TNF agents achieved
comparable protective anti-pneumococcal antibody titres com-
pared to controls. Patients treated with MTX had reduced
antibody titres to pneumococcal vaccination.298,299 Prednisolone
was not associated with reduced immunity. Renal transplant
recipients on prednisolone (mean 18 mg/day) and azathioprine
(mean 140mg/day) had near normal immunity to pneumococcus
following pneumococcal polysaccharide vaccine, compared to
healthy controls.382 Prednisolone at a dose N10 mg/day did not
affect immunity to pneumococcus in patients with chronic
pulmonary disease.383
Typhoidvaccine: In contrast, diminishedcellular andhumoral
responses to the oral administration of Salmonella enterica
serovar Typhi Ty21a vaccine was found among UC patients after
colectomy compared to healthy individuals, presumably due to
lack of colonic colonisation by the bacteria.384 On the other
hand, immunisation with oral inactivated B-subunit whole-cell
cholera vaccine was similarly effective among UC patients after
colectomy, compared to controls.385ECCO Statement OI 8H
Colectomy may impair the acquisition of immunity
following oral administration of S. enteritidis
serovar Typhi Ty21a vaccine, but not oral inacti-
vated Cholera vaccine [EL2b, RG C]. Immunisation
with parenteral S. typhi Vi polysaccharide is
preferred in patients with inflammatory bowel
disease who have had a colectomy [EL5, RG D]
Hepatitis A vaccine: In one study on the effect of HAV
immunisation, eight liver transplant recipients were compared
to 16 patients with chronic liver disease. None of the transplant
patients responded to HAV vaccine, compared to 7 of 14 with
chronic liver disease (pb0.02).386 In another study, 37 liver
transplant recipients were compared both to healthy controls and
patients with chronic liver disease. Maximal seroconversion of
transplantedpatients, observedat 7monthspost-vaccination,was
only 26%. Immunity correlated with higher leukocyte and
lymphocyte counts. No correlation was found with azathioprineor blood levels of calcineurin inhibitors.387 Another study has
reported seroconversion ratesupto41% in liver transplantpatients
and 24% in renal transplant patients after HAV immunisation.388ECCO Statement OI 8I
All patients with inflammatory bowel disease should
have Hepatitis A vaccination according to guidelines
for the general population before travel to endemic
areas. Response to Hepatitis A immunisation in
immunocompromised patients with inflammatory
bowel disease is unknown [EL4, RG C]. Monitoring
the acquisition of immunity by repeat serologic
assays should be considered [EL5, RG D]8.2. Travellers' diarrhoea
8.2.1. Background
Traveller's diarrhoea, which may be severe and incapa-
citating, is the most common health problem reported
during travel to developing countries.389 The duration is
usually 1 to 5 days, but 5–10% of travellers report diarrhoea
that lasts for 2 weeks or longer, and 1–3% report diarrhoea
that lasts four weeks or longer.390 It is unknown if patients
with IBD are at higher risk for acquiring traveller's diarrhoea.
However, this common disease, particularly if prolonged,
may lead the traveller or the clinician to a wrong diagnosis of
an exacerbation of IBD and to unnecessary self-treatment
with medication for IBD. Nevertheless, infection with
enteropathogens may provoke a relapse of quiescent IBD.
Furthermore, travellers being treated with immunomodu-
lators are at greater risk for acquiring food- andwater-borne
Salmonella sp., Cryptosporidium parvum, Isospora belli,
Microsporidia, or Cyclospora sp. infection. For these
reasons, patients with IBD should pay greater attention to
precautions regarding food and water. Cryptosporidium is
resistant to chlorination or iodination and prevention
requires use of either boiled or filtered water, or commer-
cially bottled beverages. Travellers are also best advised to
avoid swallowing water while swimming in water that may
be contaminated.
8.2.2. Treatment and self-treatment
Travellers to developing countries are often advised to
carry a fluoroquinolone for empirical self-treatment of
traveller's diarrhoea. Azithromycin, which was found to
be comparable to quinolones391 should be considered for
self-treatment of traveller's diarrhoea in the following
situations:(i) patients who take a fluoroquinolone as part of their
treatment for IBD
(ii) Travellers to countries where endemic bacteria are
known to have high levels of fluoroquinolone resis-
tance (e.g. Thailand and India)
(iii) Patients who have no response to a quinolone within
36–48 h
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fluoroquinolone is contraindicated).
Rifaximin (Xifaxan™, Salix Pharmaceuticals), an oral, non-
absorbed rifamycin antibiotic,was approved for the treatment
of traveller's diarrhoea caused by non-invasive strains of E. coli
in patients aged N12 years. Rifaximin should not be used in
patients with bloody diarrhoea or fever, or in patients who are
suspected of having traveller's diarrhoea due to pathogens
other than E. coli since rifaximin lacks efficacy against invasive
pathogens (e.g. Shigella, Salmonella, and Campylobacter
sp.). Since traveller's diarrhoea among patients with IBD has
not been studied and IBD travellersmay not themselves beable
to determine the aetiology of their diarrhoea, empirical self-
therapy with rifaximin cannot be advocated at this stage.
The immunocompromised traveller should have a lower
threshold than immune competent travellers for initiating
self-therapy for traveller's diarrhoea. If diarrhoea persists
despite antimicrobial treatment efforts should be made to
have a stool examination for ova and parasites.
ECCO Statement OI 8J
Patients with inflammatory bowel disease should
pay greater attention to precautions regarding
food and water during travel than normal. The
immunocompromised patient should have a low
threshold for initiating self-therapy for traveler's
diarrhoea with quinolones or azithromycin, but
not rifaximin. If diarrhoea does not improve within
48 h despite treatment, medical advice should be
sought [EL5, RG D]8.3. Screening for latent tuberculosis
International travellers are at increased risk for tuberculosis,
which may become evident months or years after travel. In a
multicentre, prospective cohort study, the risk of
M. tuberculosis infection in long-term immunocompetent
travellers to high-endemicity countries, even if not engaged in
health-care work, was substantial. It was of similar magnitude
to the risk for the local population.392 Though the risks and
factors associated with acquisition of tuberculosis have not
been defined in travellers with IBD, the clinician caring for
patients with IBD may have to consider the following:
(i) Immunosuppression favours progression of asympto-
matic latent tuberculosis to active disease
(ii) IBD patients not treated with immunomodulators at
the time of travel, but who acquired (asymptomatic)
TB infection during travel, may be considered for
immunomodulators at a later stage.
Attempts should therefore be made to identify latent
tuberculosis infection in these patients. Areas that are
considered to be moderately to highly endemic for tubercu-
losis include most of the countries in Africa, Central America,
South and Southeast Asia, theMiddle East, the former states of
the Soviet Union, and parts of South America. Long-termtravellers to these countries, who are at risk for tuberculosis,
are best advised to have a tuberculin skin test or interferon-
gamma release assay (QuantiFERON TB-Gold test, or ELISPOT)
before departure.287,393 If the result is negative, they should
have a repeat test approximately 8–10 weeks after return-
ing.394,395 A two-step tuberculin skin test is recommended
initially, particularly if previous exposure is likely. A positive
tuberculin skin test or interferon-gamma release assay is an
indication for chest radiograph examination and treatment.
These recommendations apply for the following IBD patients:
(i) Travellers with IBD to areas where tuberculosis is mode-
rately to highly endemic and who are receiving immuno-
modulator therapy, regardless of the duration of travel
(ii) Travellers with IBD but without immunomodulators,
who travel to areas where tuberculosis is moderately
to highly endemic for a duration of 1 month or longer
(iii) Travellers who might have prolonged exposure to
patients with active tuberculosis (such as hospitalised
patients, prisoners, or homeless population).
Particular consideration should be given to otherwise fit
young people with IBD who travel abroad before or after
University, since they frequently travel for extended periods,
stay in cheap accommodation, or engage in welfare projects
that might put them at higher risk than older people whomay
travel in greater comfort. Of note, none of the current
methods for pre- and post-travel TB screening approaches
100% sensitivity for diagnosing active tuberculosis.
ECCO Statement OI 8K
The risk of M. tuberculosis infection in long-term
travelers to countries with high-endemicity is of
similar magnitude to the average risk of the local
population [EL2, RG B]. Patients with inflammatory
bowel disease traveling for more than a month to a
moderately or highly endemic area shouldbeadvised
to have a tuberculin skin test or interferon-gamma
release assay (IGRA) before departure. If negative, it
should be repeated approximately 8–10 weeks after
returning. Caution should be exercised in recom-
mending IGRAs, since the predictive value in the
immunocompromised is uncertain. Patients with
inflammatory bowel disease on immunomodulators
should avoid contact with TB patients [EL5, RG D]
8.4. Malaria
Unless pregnant, asplenic, or concomitant HIV infection,
patients with IBD appear not to be at higher risk for acquiring
malaria or the more severe complications of malaria
compared to travellers without IBD, even when taking
immunomodulators. Recommendations for malaria preven-
tion, including prevention of mosquito bites and chemopro-
phylaxis, should be followed according to the existing
guidelines. Interactions between antimalarial drugs and
drugs for the treatment of IBD, particularly those that are
new, should be taken into consideration. Metoclopramide
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components of the anti-malarial drug Malarone) and may
decrease the prophylactic efficacy.
8.5. Prevention of insect bites
Immunocompromised IBD travellers should take extra pre-
cautions to prevent bites of insects that are known to
transmit diseases that are particularly severe in immuno-
compromised patients. Examples include reduviid bugs in
rural Brazil and sandflies on beaches in exotic locations,
which are the vectors of Chagas' disease and visceral
leishmaniasis respectively. Patients taking immunomodula-
tors should also be aware that infestation with scabies may
lead to a severe variant (Norwegian, or crusted scabies) that
is often complicated by secondary bacterial infection.
8.6. Guidelines for evaluating the returning traveller
It is beyond the scope of these guidelines to review the large
number of diseases that may affect the returning traveller.
Consequently the focus of this section is on specific issues
related to patients with IBD who return from developing
countries (see Section 8.3 for screening for latent tubercu-
losis in the returning traveller).
8.6.1. General investigations
The returning traveller from long-term travel in develop-
ing countries is best advised to have a full blood count to
identify eosinophilia, stool culture for enteric pathogens and
microscopy for ova, cysts and parasites. This is particularly
relevant to patients with IBD who are immunosuppressed.
The sensitivity of microscopic examination of a single stool
specimen for the detection of ova, cysts and parasites
generally exceed 80%.396,397 Additional stool samples, as well
as immunofluorescence or enzyme immunoassay for specific
parasites, (e.g. Giardia lamblia, C. parvum, or Entamoeba
histolytica) increase the sensitivity.397,398
Parasitic infections are more likely to be diagnosed in
patients with prolonged diarrhoea.399 Common non-infectious
causes of chronic diarrhoea in returning travellers include post-
infectious disaccharidase deficiency, irritable bowel syndrome
and undiagnosed latent disease such as villous atrophy. In many
cases of persistent diarrhoea, no known causative agent is
identified, but symptoms usually resolve within one year.397,400
8.6.2. Strongyloidiasis
Strongyloidiasis deserves special consideration. In addi-
tion to non-inflammatory diarrhoea that is often associated
with eosinophilia, S. stercoralis can produce overwhelming
infection in immunocompromised persons, as a result of its
unique ability to replicate and increase in numbers without
leaving its host.401 Strongyloidiasis can persist indefinitely
in a single host and cause hyperinfection years after
acquisition when host immunity is impaired, especially by
corticosteroid therapy. IBD patients returning from endemic
areas (Section 5.4.1) are best evaluated for possible
strongyloidiasis, even in the absence of symptoms or
eosinophilia. The sensitivity of a single stool examination
is low and repeated stool examinations are often needed.
The diagnosis is often made by serologic tests402 (Table 5).Many experts recommend therapy for seropositive patients,
even if stool examinations are negative (Sections 5.4.2
and 5.4.3).
ECCO Statement OI 8L
Long term travellers with inflammatory bowel
disease returning from developing countries
should have a stool examination for bacterial
pathogens, ova and parasites and a complete
blood count to identify eosinophilia. For long term
travellers with inflammatory bowel disease
returning from countries highly endemic for
strongyloidiasis, serological blood test for stron-
gyloidiasis should be considered [EL5, RG D]9. Vaccination and systematic work-up to
consider before introducing
immunomodulator therapy
9.1. Detailed interview
Ideally the medical history should cover:
- History of bacterial infections (especially urinary tract
infection)
- History of fungal infections
- Risk of latent or active tuberculosis:
date of the last BCG vaccination
potential contact with patients having tuberculosis
country of origin, or prolonged stay in an area endemic for
tuberculosis
history of treatment for latent or active tuberculosis
- History of varicella-zoster virus infection (chickenpox/
shingles)
- History of herpes simplex virus infection
- Immunisation status for hepatitis B
- History of travel and/or living in tropical area or countries
with endemic infections
- Future plans to travel abroad to endemic areas.
9.2. Physical examination
General physical examinationbest includes a search for features
that often pass without comment, because they are of minor
significance in peoplewho are generally healthy, but whichmay
have substantial implications when immunosuppressed:
- Systemic or local signs of active infection (including
gingivitis, oral or vaginal candidiasis, or intertrigo as features
of fungal infection)
- Cervical smear.
9.3. Laboratory tests
Many opportunistic infections are preventable and the po-
tential for severe infection during immunosuppression can
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starting immunomodulator therapy.
Ideally, baseline tests, potentially performed at diagnosis
(see below), should include:
- Neutrophil and lymphocyte cell count
- C-reactive protein (a strikingly elevated CRP indicates an
underlying infective process, but may also be caused by
inflammation)
- Urine analysis in patients with prior history of urinary
tract infection or urinary symptoms
- Varicella zoster virus (VZV) serology in patients without a
reliable history of varicella immunisation
- Hepatitis B virus serology
- Human immunodeficiency virus (HIV) serology after
appropriate counselling
- Eosinophil cell count, stool examination and strongyloi-
diasis serology (for returning travellers).
9.4. Screening for tuberculosis
Screening for tuberculosis should be considered before using
high dose corticosteroids or immunomodulators other than
anti-TNF therapy, although it is considered mandatory for the
latter group.
- Clinical context of risk (gathered from a detailed history,
above)
- Chest radiograph
- Tuberculin skin test or interferon gamma release assay
(according to country-specific guidelines).
9.5. Vaccination
Vaccines are best given before introduction of immunomo-
dulator therapy. Consideration could reasonably be given to a
vaccination programme at diagnosis of inflammatory bowel
disease, since around 80% of patients will be treated with
corticosteroids, 40% with thiopurines and 20% with anti-TNF
therapy.
As in the general population, the immunisation status of
patients with inflammatory bowel disease should be checked
and vaccination considered for routinely administered
vaccines: tetanus, diphtheria, poliomyelitis.
In addition, every patient with inflammatory bowel
disease should be considered for the five following vaccines,
ideally at diagnosis for the reasons above:
- VZV varicella vaccine (if there is no medical history of
chickenpox, shingles, or VZV vaccination and VZV serology
is negative
- Human papilloma virus
- Influenza (trivalent inactivated vaccine) once a year
- Pneumococcal polysaccharide vaccine
- Hepatitis B vaccine in all HBV seronegative patients.
Vaccines for patients on immunomodulators traveling in
developing countries or frequently traveling around the
world should be discussed with an appropriate specialist.Contributors
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